

AtriCure, Inc.
Form 424B5
February 12, 2014
Table of Contents

Filed Pursuant to Rule 424(b)(5)
Registration No. 333-193370

The information in this prospectus supplement and the accompanying prospectus is not complete and may be changed. This prospectus supplement and the accompanying prospectus are not an offer to sell these securities, nor are they soliciting offers to buy these securities, in any jurisdiction where the offer or sale is not permitted.

Subject to Completion, dated February 12, 2014

PROSPECTUS SUPPLEMENT

(To Prospectus dated February 6, 2014)

Shares

**AtriCure, Inc.
Common Stock**

\$ per share

AtriCure, Inc. is offering shares of common stock. In addition, the selling securityholders are offering shares of our common stock. We will not receive any proceeds from the sale of shares to be offered by the selling securityholders.

The last reported sale price of our common stock on February 11, 2014 was \$ 20.26 per share.

Trading symbol: Nasdaq Global Market ATRC.

This investment involves risks. See **Risk Factors** beginning on page 20 of our Annual Report on Form 10-K for the year ended December 31, 2012, page S-5 of this prospectus supplement and on page 5 of the accompanying prospectus.

	Per Share	Total
Public Offering Price	\$	\$
Underwriting discount	\$	\$
Proceeds, before expenses, to AtriCure, Inc	\$	\$
Proceeds, before expenses, to selling securityholders	\$	\$

The underwriters have a 30-day option to purchase up to _____ additional shares of common stock from us to cover over-allotments, if any. If the underwriters exercise this option in full, the total underwriting discount will be \$ _____, and our total proceeds to us, before expenses, will be \$ _____.

The underwriters expect to deliver the shares against payment on or about February _____, 2014.

Neither the Securities and Exchange Commission nor any state securities commission has approved of anyone's investment in these securities or determined if this prospectus supplement and the accompanying prospectus are truthful or complete. Any representation to the contrary is a criminal offense.

Piper Jaffray

Sole Book-Running Manager

Canaccord Genuity

**Leerink
Barrington Research**

Stifel

The date of this prospectus supplement is February _____, 2014.

Table of Contents**TABLE OF CONTENTS**

Prospectus Supplement	
<u>PROSPECTUS SUPPLEMENT SUMMARY</u>	S-1
<u>THE OFFERING</u>	S-4
<u>RISK FACTORS</u>	S-5
<u>SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS</u>	S-6
<u>USE OF PROCEEDS</u>	S-7
<u>CAPITALIZATION</u>	S-8
<u>DILUTION</u>	S-9
<u>SELLING SECURITYHOLDERS</u>	S-10
<u>UNDERWRITING</u>	S-11
<u>LEGAL MATTERS</u>	S-13
<u>EXPERTS</u>	S-13
<u>WHERE YOU CAN FIND MORE INFORMATION</u>	S-13
<u>IMPORTANT INFORMATION INCORPORATED BY REFERENCE</u>	S-14

We provide information to you about this offering of shares of our common stock in two separate documents that are bound together: (1) this prospectus supplement, which describes the specific details regarding this offering and also adds to and updates information contained in the accompanying prospectus and the documents incorporated by reference into this prospectus supplement and the accompanying prospectus; and (2) the accompanying prospectus, which provides general information, some of which may not apply to this offering. Generally, when we refer to this prospectus, we are referring to both documents combined. If information in this prospectus supplement is inconsistent with the accompanying prospectus or in any document incorporated by reference that was filed with the Securities and Exchange Commission before the date of this prospectus supplement, you should rely on this prospectus supplement.

You should rely only on information contained in or incorporated by reference into this prospectus supplement and the accompanying prospectus. We have not, and the selling securityholders and the underwriters have not, authorized anyone to provide you with information that is different. We and the selling securityholders are offering to sell and seeking offers to buy shares of our common stock only in jurisdictions where offers and sales are permitted. The information contained in this prospectus supplement, the accompanying prospectus and the documents incorporated by reference herein and therein are accurate only as of their respective dates, regardless of the time of delivery of this prospectus supplement or of any sale of our common stock. You should read this prospectus supplement, the accompanying prospectus, the documents incorporated by reference in this prospectus supplement and the accompanying prospectus, and any free writing prospectus that we have authorized for use in connection with this offering, in their entirety before making an investment decision. You also should read and consider the information in the documents to which we have referred you in the sections of this prospectus supplement titled *Where You Can Find More Information* and *Important Information Incorporated By Reference*.

Unless otherwise stated in this prospectus supplement, we have assumed throughout this prospectus supplement that the over allotment option granted to the underwriters will not be exercised.

Table of Contents

PROSPECTUS SUPPLEMENT SUMMARY

*The items in the following summary are described in more detail later in this prospectus supplement, in the accompanying prospectus and in the documents incorporated by reference herein and therein. This summary provides an overview of selected information and does not contain all the information you should consider before investing in our common stock. Therefore, you should carefully read this prospectus supplement and the accompanying prospectus, including the documents incorporated by reference, which are described under *Where You Can Find More Information* and *Incorporation of Documents by Reference* in this prospectus supplement. You should also carefully consider the matters discussed in the sections in this prospectus entitled *Risk Factors* and in the accompanying prospectus and in other periodic reports incorporated herein by reference.*

Our Business

We are a medical device company and a leader in developing, manufacturing and selling innovative cardiac surgical ablation systems designed to create precise lesions, or scars, in cardiac, or heart, tissue for the treatment of atrial fibrillation, or AF, and systems for the exclusion of the left atrial appendage. We are the only company with a system cleared by the United States Food and Drug Administration, or FDA, for the treatment of patients with persistent and long-standing persistent AF. We have two primary product lines for the ablation of cardiac tissue. Our primary product line for the ablation of cardiac tissue, which accounts for a majority of our revenue, is the AtriCure Synergy Ablation System, a bipolar ablation clamp system and related radiofrequency ablation devices. We also offer a cryoablation product line, which features reusable and disposable cryoablation devices. Additionally, we offer the AtriClip Gillinov-Cosgrove Left Atrial Appendage System, or AtriClip system, which is designed to safely and effectively exclude the left atrial appendage.

Cardiothoracic surgeons have adopted our radio-frequency, or RF, ablation and cryoablation systems to treat AF in an estimated 125,000 patients since January 2003, and we believe that we are currently the market leader in the surgical treatment of AF. Our products are utilized by cardiothoracic surgeons during concomitant open-heart surgical procedures and also during sole-therapy minimally invasive cardiac ablation procedures. During a concomitant open procedure, the surgeon ablates cardiac tissue and/or excludes the left atrial appendage, secondary, or concomitant, to a primary cardiac procedure such as a valve or coronary bypass. Additionally, cardiothoracic surgeons have adopted our products as a treatment alternative for AF patients who may be candidates for sole-therapy minimally invasive surgical procedures. Our Synergy System, which includes our Isolator[®] Synergy clamps, a radiofrequency generator and related switchbox, is cleared by the FDA, for the treatment of patients with persistent and long-standing persistent AF during open-heart concomitant coronary artery bypass grafting and/or valve replacement or repair procedures. To date, none of our other products have been approved or cleared by the FDA for the treatment of other forms of AF or for other uses for the treatment of AF. Additionally, the FDA has not cleared or approved our products for a reduction in the risk of stroke. We anticipate that substantially all of our revenue for the foreseeable future will relate to products we currently sell, or are in the process of developing, which surgeons generally use to ablate cardiac tissue for the treatment of AF or for the exclusion of the left atrial appendage.

AF affects approximately 1% of the population in the United States. It is the most common cardiac arrhythmia, or irregular heartbeat, encountered in clinical practice and accounts for more doctor visits and hospital days than any other cardiac arrhythmia. AF is a condition wherein abnormal electrical impulses cause the atria, or upper chambers of the heart, to fibrillate, or quiver, at rapid

Table of Contents

rates of 400 to 600 beats per minute. As a result of this quivering, blood in the atria may become static, creating an increased risk that a blood clot will form and cause a stroke or other serious complications. If AF persists, patients often progress from experiencing AF intermittently to having AF continuously, a condition that is more difficult to treat. Symptoms of AF may include heart palpitations, dizziness, fatigue and shortness of breath, and these symptoms may be debilitating and life threatening in some condition that is more difficult to treat. Symptoms of AF may include heart palpitations, dizziness, fatigue and shortness of breath, and these symptoms may be debilitating and life threatening in some cases. Although there is often no specific cause of AF, the condition is often associated with high blood pressure and other forms of heart disease. In most cases, AF is associated with cardiovascular disease, in particular hypertension, congestive heart failure, left ventricular dysfunction, coronary artery disease and valvular disease.

In the United States we primarily sell our products to medical centers through our direct sales force. AtriCure Europe, B.V., our wholly-owned subsidiary incorporated and based in the Netherlands, markets and sells our products throughout Europe and the Middle East, primarily through distributors, while in certain markets, such as Germany and the Benelux region, we sell directly to medical centers. Additionally, we sell our products to other international distributors, primarily in Asia, South America and Canada. Our business is primarily transacted in U.S. dollars with the exception of transactions with our European subsidiary which are substantially transacted in Euros.

Recent Developments

Acquisition of Endoscopic Technologies, Inc.

On December 31, 2013, AtriCure completed a merger pursuant to the Merger Agreement, dated as of December 19, 2013, among AtriCure, Niners Merger Sub, LLC, a Delaware limited liability company and a subsidiary of AtriCure, Endoscopic Technologies, Inc., a Delaware corporation, or Estech, and Fortis Advisors LLC, solely in its capacity as representative of the stockholders. We refer to this as the Merger Agreement.

Pursuant to the Merger Agreement, AtriCure issued an aggregate of 2,126,343 shares of AtriCure common stock to shareholders of Estech as consideration for and in connection with the closing of the merger. All of such shares were offered and sold in a private offering to accredited investors pursuant to the exemption provided by Section 4(2) of the Securities Act of 1933, as amended.

Estech, a privately held company based in San Ramon, California, develops and markets a portfolio of innovative surgical ablation devices that enable physicians to perform a variety of traditional and minimally invasive procedures using Estech's proprietary temperature controlled RF energy.

Financial Information

On January 9, 2014, AtriCure announced that preliminary revenue for the fourth quarter of 2013 is expected to be approximately \$21.9 million, reflecting growth of approximately 19% over the fourth quarter of 2012. Based on these preliminary estimates, revenue from U.S. customers for the fourth quarter of 2013 is expected to be \$16.4 million, reflecting growth of 20% over the same period in 2012, and revenue from international customers is expected to be \$5.5 million, reflecting growth of 17%, or 14% on a constant currency basis over the same period in 2012.

Preliminary revenue for full year 2013 is expected to be \$81.9 million, reflecting year over year growth of 17% over full year 2012.

Table of Contents

The preliminary financial results for the fourth quarter and full year ended December 31, 2013 are pending completion of our annual report on Form 10-K for the fiscal year ended December 31, 2013 and accordingly are subject to change.

Corporate Information

We were incorporated in the State of Delaware as AtriCure, Inc. on October 31, 2000 in connection with a spin-off transaction from Enable Medical Corporation, in which shares of our common stock were distributed to the Enable shareholders. The spin-off was intended to allow us to focus on the development of products designed to treat AF and to raise capital for that purpose, while Enable continued its broader research and manufacturing activities. On August 5, 2005, we completed an initial public offering of our common stock. On August 10, 2005, we acquired Enable Medical Corporation, the manufacturer of our Isolator clamps, which are an essential part of our Synergy System. Additionally, in December 2005, we formed AtriCure Europe, B.V. Our principal executive offices are located at 6217 Centre Park Drive, West Chester, Ohio 45069, and our main telephone number is (513) 755-4100. Our internet website address is <http://www.atricure.com>. We do not incorporate by reference into this prospectus supplement or the accompanying prospectus the information on, or accessible through, our website, and you should not consider it as part of this prospectus supplement or the accompanying prospectus.

Table of Contents

THE OFFERING

Common stock offered by AtriCure shares

Common stock offered by the Selling Securityholders shares

Common stock to be outstanding after this offering shares

Use of proceeds We intend to use the net proceeds from this offering for general corporate purposes and working capital. We will not receive any proceeds from the sale of shares to be offered by the selling securityholders.

Risk factors You should read the Risk Factors beginning on page 20 of our Annual Report on Form 10-K for the year ended December 31, 2012, on page S-4 of this prospectus supplement, on page 5 of the accompanying prospectus and in the documents incorporated by reference in this prospectus supplement and the accompanying prospectus for a discussion of factors to consider before deciding to purchase shares of our common stock.

Nasdaq Global Market symbol ATRC

The number of shares of common stock to be outstanding after this offering as reflected in the table above is based on the actual number of shares outstanding as of September 30, 2013 which was 21,017,910, and does not include, as of that date:

2,472,354 shares of common stock issuable upon the exercise of outstanding options, with a weighted average exercise price of \$8.59 per share;

1,574,587 shares of common stock reserved for future issuance under our 2005 Equity Incentive Plan, as amended.

S-4

Table of Contents

RISK FACTORS

Before you make a decision to invest in our common stock, you should consider carefully the risks described below, together with other information in this prospectus supplement, the accompanying prospectus and the information incorporated by reference herein and therein. If any of the following events actually occur, our business, operating results, prospects or financial condition could be materially and adversely affected. This could cause the trading price of our common stock to decline and you may lose all or part of your investment. The risks described below are not the only ones that we face. Additional risks not presently known to us or that we currently deem immaterial may also significantly impair our business operations and could result in a complete loss of your investment.

See Risk Factors beginning on page 20 of our Annual Report on Form 10-K for the year ended December 31, 2012 and on page 5 of the accompanying prospectus, which are incorporated herein by reference.

Risks Related to This Offering

Management will have broad discretion as to the use of the proceeds from this offering, and we may not use the proceeds effectively.

We have not designated any portion of the net proceeds from this offering to be used for any particular purpose. Accordingly, our management will have broad discretion as to the application of the net proceeds from this offering, and could spend the proceeds in ways that do not necessarily improve our operating results or enhance the value of our common stock.

You will experience immediate dilution in the book value per share of the common stock you purchase.

Because the price per share of our common stock being offered is substantially higher than the book value per share of our common stock, you will suffer substantial dilution in the net tangible book value of the common stock you purchase in this offering. After giving effect to the sale by us of _____ shares of common stock in this offering, and based on a public offering price of \$ _____ per share in this offering and a net tangible book value of our common stock of \$36.2 million, or \$1.72 per share, as of September 30, 2013, if you purchase shares of common stock in this offering, you will suffer immediate and substantial dilution of \$ _____ per share in the net tangible book value of the common stock. If the underwriters exercise their over-allotment option, you will experience additional dilution. See Dilution on page S-8 for a more detailed discussion of the dilution you will incur in connection with this offering.

Risks Relating to our Business

If we do not achieve our projected development goals in the quantities or time frames we estimate, the commercialization of our products may be delayed and our business prospects may suffer. The assumptions underlying our product placement and development goals also may prove to be materially inaccurate.

From time to time, we estimate the timing of the accomplishment of various scientific, clinical, regulatory and other product development goals. These goals may include the commencement or completion of scientific studies and clinical trials, the timing and number of product placements and the submission of regulatory filings. We also may disclose projected expenditures or other forecasts for future periods in information that we furnish to the SEC from time to time. These and other projections are based on management's current expectations and may not contain sufficient margin of error or cushion for any specific uncertainties, or for the uncertainties inherent in all forecasting. The actual timing of our product placement and development goals and actual expenditures or other financial results can vary dramatically compared to our estimates, in some cases for reasons beyond our control. If we do not meet projections as announced from time to time, the development, placement and commercialization of our

Table of Contents

products may be delayed and our business prospects may suffer. The assumptions management has used to produce these projections may significantly change or prove to be inaccurate. Accordingly, you should not unduly rely on any of these forward looking statements.

Our ability to use net operating losses to offset future taxable income may be subject to certain limitations.

We currently have significant net operating losses (NOLs) that may be used to offset future taxable income. In general, under Section 382 of the Internal Revenue Code of 1986, as amended, or the Code, a corporation that undergoes an ownership change is subject to limitations on its ability to utilize its pre-change NOLs to offset future taxable income. This offering or future changes in our stock ownership, some of which are outside of our control, could result in an ownership change under Section 382 of the Code, which would significantly limit our ability to utilize NOLs to offset future taxable income.

SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS

This prospectus supplement and the accompanying prospectus, including the documents that we incorporate by reference herein and therein, and other information that we may furnish to the Securities and Exchange Commission from time to time contain forward looking statements about us and our industry that involve substantial risks and uncertainties. We intend such forward looking statements to be covered by the safe harbor provisions for forward looking statements contained in Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. All statements, other than statements of historical facts, included in this prospectus supplement and the accompanying prospectus and information that we furnish to or file with the Securities and Exchange Commission regarding our strategy, future operations, future financial position, future net sales, projected expenses, products placements, performance and acceptance, prospects and plans and management's objectives, as well as the growth of the overall market for our products in general and certain products in particular and the relative performance of other market participants are forward looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievement to be materially different from those expressed or implied by the forward looking statements.

In some cases, you can identify forward looking statements by terms such as anticipate, believe, estimate, expect, intend, may, might, project, will, would, should, could, can, predict, potential, continue, objective, or the negative of these terms, and similar expressions. However, not all forward looking statements contain these identifying words. These forward looking statements reflect our current views about future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward looking statements. Our actual results may differ materially from those anticipated in these forward looking statements as a result of various factors, including but not limited to:

the ability of our products to achieve widespread market acceptance within the medical community as a standard treatment alternative for the surgical treatment of AF during open-heart surgical procedures and as a sole-therapy minimally invasive procedure;

our receipt of additional FDA approvals to promote our products for the treatment of AF or reduction in stroke risk, which is conditioned on the safety and efficacy of our products as demonstrated in clinical trials;

our reliance that our ablation and ablation related products will continue to be a primary source of revenue and will not become obsolete;

Table of Contents

competition from new and existing products and procedures in the highly competitive medical device industry;

failure of third party payors to reimburse our customers for the use of our clinical diagnostic products or reduction of reimbursement levels, which could harm our ability to promote and sell our products;

failure of our products to perform as expected or to obtain certain approvals or the questioning of the reliability of the technology on which our products are based or the questioning of the promotion by regulatory authorities of our products as off-label , which could cause lost revenue, delayed or reduced market acceptance of our products, increased costs and damage to our reputation;

our ability to consummate acquisitions or, if consummated, to successfully integrate acquired businesses into our operations and to recognize the benefits of acquisitions, including potential synergies and cost savings;

failure of an acquisition or acquired company to achieve its plans and objectives generally, and risk that proposed or consummated acquisitions may disrupt operations or pose difficulties in employee retention or otherwise affect financial or operating results;

our ability to retain our current employees and/or require additional qualified personnel, upon whom the success of our business is highly dependent; and

those set forth under Risk Factors in our Annual Report on Form 10 K.

These forward looking statements represent our estimates and assumptions only as of the date of this prospectus supplement. Unless required by U.S. federal securities laws, we do not intend to update any of these forward looking statements to reflect circumstances or events that occur after the statement is made or to conform these statements to actual results. The following discussion should be read in conjunction with the consolidated financial statements and notes thereto appearing in our Annual Report on Form 10 K. Our actual results may differ materially from those anticipated in these forward looking statements as a result of various factors, including those set forth under Risk Factors in this prospectus supplement and the accompanying prospectus.

You should carefully consider all the information in or incorporated by reference in this prospectus supplement and the accompanying prospectus prior to investing in our securities.

USE OF PROCEEDS

We estimate that the net proceeds from the sale of the shares of common stock we are offering will be approximately \$ million, or approximately \$ million if the underwriters exercise their over allotment option in full. Net proceeds is what we expect to receive after paying the underwriting discount and other expenses of this offering payable by us.

We will use the net proceeds from the sale of the common stock for general corporate purposes and working capital.

Until we use the net proceeds of this offering, we may invest the funds in short term, investment grade, interest bearing securities.

We will not receive any proceeds from the sale of shares to be offered by the selling securityholders.

Table of Contents**CAPITALIZATION**

The following table sets forth our capitalization as of September 30, 2013 on an actual basis and on an as adjusted basis to reflect this offering.

The table should be read in conjunction with, and is qualified in its entirety by reference to, our unaudited historical financial statements and the accompanying notes included in our Quarterly Report on Form 10 Q for the quarter ended September 30, 2013, which are incorporated by reference herein.

	September 30, 2013	
	Actual (unaudited)	As Adjusted (unaudited)
	(dollars in thousands)	
Stockholders equity:		
Common Stock, \$0.001 par value; 90,000,000 shares authorized; 21,017,910 shares issued and outstanding; shares issued and outstanding as adjusted	\$ 21	\$
Preferred stock, \$0.001 par value; 10,000,000 shares authorized; no shares issued		
Additional paid-in capital	153,420	
Accumulated deficit	117,233	
Total stockholders' equity	\$ 36,245	\$

The information above is based on 21,017,910 shares of our common stock outstanding as of September 30, 2013 and does not include:

2,472,354 shares of common stock issuable upon the exercise of options outstanding as of September 30, 2013, at a weighted average exercise price of \$8.59 per share (including 171,542 shares of common stock that were issued upon the exercise of options from September 30, 2013 through February 11, 2014 and options to purchase 9,970 shares of common stock that were forfeited or expired subsequent to September 30, 2013);

468,500 options granted under our 2005 Equity Incentive Plan, as amended, from September 30, 2013 through February 11, 2014; and

1,000 restricted shares of common stock that were forfeited to us and returned to the pool of authorized shares available for issuance under our 2005 Equity Incentive Plan, as amended, from September 30, 2013 through February 11, 2014.

Table of Contents**DILUTION**

Our net tangible book value on September 30, 2013 was approximately \$36.2 million, or \$1.72 per share of common stock. Net tangible book value is total assets minus the sum of liabilities and intangible assets. Net tangible book value per share is net tangible book value divided by the total number of shares of common stock outstanding. After giving effect to the sale of shares of common stock offered by us in this offering at a price of \$ per share, less the underwriting discounts and other expenses of this offering payable by us, our pro forma as adjusted net tangible book value on September 30, 2013 would have been approximately \$ million, or \$ per share of common stock. The following table illustrates this dilution on a per share basis:

Public offering price per share	\$
Net tangible book value per share as of September 30, 2013	\$ 1.72
Increase in net tangible book value per share attributable to offering	\$
Net tangible book value per share as of September 30, 2013 after giving effect to the offering	\$
Dilution per share to investors in the offering	\$

The above discussion and table are based on 21,017,910 common shares outstanding at September 30, 2013, and do not include, as of that date:

2,472,354 shares of common stock issuable upon the exercise of options outstanding as of September 30, 2013, at a weighted average exercise price of \$8.59 per share (including 171,542 shares of common stock that were issued upon the exercise of options from September 30, 2013 through February 11, 2014 and options to purchase 9,970 shares of common stock that were forfeited or expired subsequent to September 30, 2013);

468,500 options granted under our 2005 Equity Incentive Plan, as amended, from September 30, 2013 through February 11, 2014; and

1,000 restricted shares of common stock that were forfeited to us and returned to the pool of authorized shares available for issuance under our 2005 Equity Incentive Plan, as amended, from September 30, 2013 through February 11, 2014.

Table of Contents**SELLING SECURITYHOLDERS**

The table below sets forth certain information known to us with respect to the beneficial ownership of the shares of our common stock held by the selling securityholders as of January 31, 2014, the number of shares being offered hereby and information with respect to shares to be beneficially owned by the selling securityholders after the completion of this offering. In the table below, the percentage of shares beneficially owned is based on 23,363,948 shares of our common stock outstanding as of January 31, 2014. Beneficial ownership is determined under the rules of the SEC and generally includes voting or investment power with respect to securities. The entities named in the table below have sole voting and sole investment power with respect to all shares beneficially owned.

Except as described herein, none of the selling securityholders has had any material relationship with us except with respect to ownership of the shares of common stock.

Name and address of beneficial owner	Shares beneficially owned prior to this offering		Shares beneficially owned after offering		
	Common stock	Percentage of shares	Shares to be sold in offering	Common stock	Percentage of shares
Camden Partners (1) 500 East Pratt Street, Suite 1200 Baltimore, MD 21202	631,790	2.65%			
Saints Capital Everest L.P. (2)(3) 2020 Union Street San Francisco, CA 94123	1,470,367	6.16%			

- (1) This selling securityholder's holdings consist of 585,405 shares held by Camden Partners Strategic Fund II-A, L.P., 34,727 shares held by Camden Partners Strategic Fund II-B, L.P. and 11,658 shares held by Camden Partners Holdings, LLC. Camden Partners Strategic II, LLC is the general partner of Camden Partners Strategic Fund II-A, L.P. and Camden Partners Strategic Fund II-B, L.P. David L. Warnock and Donald W. Hughes each may be deemed to share voting and investment power with respect to the securities held by these entities and disclaims beneficial ownership of the securities held by these entities, except as to his pecuniary interest therein. Richard M. Johnston, who has served as a director of AtriCure since June 2002 and as Chairman of the Board since February 2005, served as a Managing Member of both Camden Partners Holdings, LLC and Camden Partners Strategic II, LLC, and is now a Retired Member of each.
- (2) Includes shares of our common stock over which the selling securityholder has sole voting and dispositive power as well as 99,253 shares of our common stock held in escrow over which Fortis Advisors LLC in its capacity as representative of the selling securityholder has sole voting power. Also includes up to an aggregate of 280,000 shares of our common stock that may be issued as Earn-Out.
- (3) The general partner of Saints Capital Everest L.P. is Saints Capital Everest LLC, the managers of which are Scott Halsted, Kenneth Sawyer, David Quinlivan and Ghia Griarte, each of whom may be deemed to share voting and investment power with respect to the securities and disclaims beneficial ownership of the securities, except to the extent of his/her pecuniary interest therein.

Table of Contents

UNDERWRITING

We and the selling securityholders are offering the shares of common stock described in this prospectus supplement through Piper Jaffray & Co. as the sole book running manager. We and the selling securityholders have entered into a firm commitment underwriting agreement with Piper Jaffray, as representative of the several underwriters. Subject to the terms and conditions of the underwriting agreement, we and the selling securityholders have agreed to sell to the underwriters, and the underwriters have agreed to purchase from us and the selling securityholders, _____ shares and _____ shares of common stock, respectively.

Underwriter	Number of Shares
Piper Jaffray & Co.	
Canaccord Genuity Inc.	
Leerink Partners LLC	
Stifel Nicolaus & Company, Incorporated.	
Barrington Research Associates, Inc	
Total	

Each underwriter is committed to purchase all the shares of common stock offered by us and the selling securityholders if it purchases any shares, other than those shares covered by the over allotment option described below.

Each underwriter proposes to offer the common stock directly to the public at the initial public offering price set forth on the cover page of this prospectus supplement and to certain dealers at that price less a concession not in excess of \$ _____ per share. After the offering, these figures may be changed by the underwriters.

We have granted the underwriters an option to buy up to _____ additional shares of common stock from us to cover over allotments. The underwriters may exercise this option at any time and from time to time during the 30 day period from the date of this prospectus supplement. If any additional shares of common stock are purchased, the underwriters will offer the additional shares on the same terms as those on which the shares are being offered.

The underwriting fee is equal to the public offering price per share of common stock less the amount paid by the underwriters to us per share of common stock. The following table shows the per share and total underwriting discount to be paid to the underwriters in this offering assuming both no exercise and full exercise of the underwriters option to purchase additional shares.

	With no Over- Allotment	With Over- Allotment
Public offering price	\$	\$
Underwriting discounts and commissions paid by us, per share	\$	\$
Underwriting discounts and commissions paid by the selling security holders, per share	\$	\$

We estimate that the total fees and expenses payable by us, excluding underwriting discount, will be approximately \$250,000, which includes \$ _____ that we have agreed to reimburse the underwriters for the fees incurred by it in connection with the offering. The selling shareholders will bear a pro rata portion of the underwriting discounts and commissions as set forth in the table above. We will bear all other expenses of this offering.

Table of Contents

We have agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act, or to contribute to payments that the underwriters may be required to make in respect of those liabilities.

We, each of our directors and executive officers and one of the selling securityholders are subject to lock up agreements that prohibit us and them from offering for sale, pledging, assigning, encumbering, announcing the intention to sell, selling, contracting to sell, granting any option, right or warrant to purchase, or otherwise transferring or disposing of, any shares of our common stock or any securities convertible into or exercisable or exchangeable for shares of our common stock for a period of at least 90 days following the date of this prospectus supplement without the prior written consent of Piper Jaffray. Notwithstanding the forgoing, one director may be permitted to offer and sell up to 200,000 of his shares after 30 days following the date of this prospectus supplement. The lock up agreement does not prohibit our directors and executive officers from transferring shares of our common stock for bona fide estate or tax planning purposes, subject to certain requirements, including that the transferee be subject to the same lock up terms.

The lock up agreements do not prohibit us from issuing shares upon the exercise or conversion of securities outstanding on the date of this prospectus supplement. The lock up provisions do not prevent us from selling shares to the underwriters pursuant to the underwriting agreement, or from granting options to acquire securities under our existing stock option plans or issuing shares upon the exercise or conversion of securities outstanding on the date of this prospectus supplement.

The 90 day lock up period in all of the lock up agreements is subject to extension if (i) during the last 17 days of the lock up period we issue an earnings release or material news or a material event relating to us occurs or (ii) prior to the expiration of the lock up period, we announce that we will release earnings results during the 16 day period beginning on the last day of the lock up period, in which case the restrictions imposed in these lock up agreements shall continue to apply until the expiration of the 18 day period beginning on the issuance of the earnings release or the occurrence of the material news or material event, unless Piper Jaffray waives the extension in writing.

Our shares are quoted on the Nasdaq Global Market under the symbol ATRC.

To facilitate the offering, the underwriters may engage in transactions that stabilize, maintain or otherwise affect the price of our common stock during and after the offering. Specifically, the underwriters may over allot or otherwise create a short position in the common stock for its own account by selling more shares of common stock than we have sold to it. Short sales involve the sale by the underwriters of a greater number of shares than the underwriters are required to purchase in the offering. The underwriters may close out any short position by either exercising its option to purchase additional shares or purchasing shares in the open market.

In addition, the underwriters may stabilize or maintain the price of the common stock by bidding for or purchasing shares of common stock in the open market and may impose penalty bids. If penalty bids are imposed, selling concessions allowed to syndicate members or other broker dealers participating in the offering are reclaimed if shares of common stock previously distributed in the offering are repurchased, whether in connection with stabilization transactions or otherwise. The effect of these transactions may be to stabilize or maintain the market price of the common stock at a level above that which might otherwise prevail in the open market. The imposition of a penalty bid may also affect the price of the common stock to the extent that it discourages resales of the common stock. The magnitude or effect of any stabilization or other transactions is uncertain. These transactions may be effected on the Nasdaq Global Market or otherwise and, if commenced, may be discontinued at any time. The underwriters may also engage in passive market making transactions in our common stock. Passive market making consists of displaying bids on the Nasdaq Global Market is limited by the prices of independent market makers and effecting purchases limited by those prices in response to order flow. Rule 103 of Regulation M

Table of Contents

promulgated by the Commission limits the amount of net purchases that each passive market maker may make and the displayed size of each bid. Passive market making may stabilize the market price of the common stock at a level above that which might otherwise prevail in the open market and, if commenced, may be discontinued at any time.

This prospectus supplement and the accompanying prospectus in electronic format may be made available on the web sites maintained by the underwriters and the underwriters may distribute prospectuses and prospectus supplements electronically.

From time to time in the ordinary course of its businesses, the underwriters and certain of their affiliates have engaged, and may in the future engage, in commercial banking or investment banking transactions with us and our affiliates.

LEGAL MATTERS

Certain legal matters with respect to the validity of common stock offered by this prospectus supplement will be passed upon for us by Keating Muething & Klekamp PLL, Cincinnati, Ohio. Certain legal matters in connection with the common stock offered in this prospectus supplement will be passed upon for the underwriters by Goodwin Procter LLP, New York, New York.

EXPERTS

The financial statements incorporated in this prospectus supplement and the accompanying prospectus by reference from our Annual Report on Form 10-K for the year ended December 31, 2012 and the effectiveness of AtriCure, Inc.'s internal control over financial reporting have been audited by Deloitte & Touche LLP, an independent registered public accounting firm, as stated in their reports, which are incorporated herein by reference. Such financial statements have been so incorporated in reliance upon the reports of such firm given upon their authority as experts in accounting and auditing.

WHERE YOU CAN FIND MORE INFORMATION

We have filed with the SEC a registration statement on Form S-3 under the Securities Act of 1933 with respect to the shares of common stock we are offering under this prospectus supplement. This prospectus supplement and the accompanying prospectus do not contain all of the information set forth in the registration statement and the exhibits to the registration statement. For further information with respect to us and the securities we are offering under this prospectus supplement, we refer you to the registration statement and the exhibits and schedules filed as a part of the registration statement. Statements contained in this prospectus supplement as to the contents of any contract or any other document referred to are not necessarily complete, and in each instance, we refer you to the copy of the contract or other document filed as an exhibit to the registration statement. Each of these statements is qualified in all respects by this reference.

We also file annual reports, quarterly reports, proxy statements, and other documents with the SEC under the Securities Exchange Act of 1934, as amended (the Exchange Act). The public may read and copy any materials we file with the SEC, including the registration statement of which this prospectus supplement and the accompany prospectus are a part, at the SEC's Public Reference Room at 100 F Street, NE, Room 2521, Washington, D.C. 20549. The public may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. Also, the SEC maintains an internet site www.sec.gov that contains reports, proxy and information statements and other information regarding issuers that file electronically with the SEC, including AtriCure. General information about AtriCure, including our annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, as well as any amendments and exhibits to those reports, are

Table of Contents

available free of charge through our website at www.atricure.com as soon as reasonably practicable after we file them with, or furnish them to, the SEC. Information on or available through our website is not incorporated into this prospectus supplement and the accompanying prospectus.

IMPORTANT INFORMATION INCORPORATED BY REFERENCE

The SEC allows incorporation by reference into this prospectus supplement and the accompanying prospectus of information that we file with the SEC. This permits us to disclose important information to you by referencing these filed documents. Any information referenced this way is considered part of this prospectus supplement and the accompanying prospectus, and any information filed by us with the SEC and incorporated herein by reference subsequent to the date of this prospectus supplement and the accompanying prospectus will automatically be deemed to update and supersede this information. We incorporate by reference the following documents which have been filed with the SEC:

Our Annual Report on Form 10-K for our fiscal year ended December 31, 2012 as filed with the SEC on March 8, 2013;

Our Quarterly Reports on Form 10-Q for our fiscal quarters ended March 31, 2013, June 30, 2013 and September 30, 2013, as filed with the SEC on May 3, 2013, August 2, 2013 and November 1, 2013, respectively;

Our definitive proxy statement on Schedule 14A, relating to the annual meeting of stockholders held on May 23, 2013, as filed with the SEC on April 12, 2013; and

Our Current Reports on Form 8-K filed on January 16, 2013, January 31, 2013, March 11, 2013, March 29, 2013, May 24, 2013, September 3, 2013, December 19, 2013, and January 2, 2014.

All documents filed by us under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act from the date of this prospectus supplement and the accompanying prospectus until the sale of all securities registered hereunder or the termination of the registration statement shall be deemed to be incorporated in this prospectus supplement and the accompanying prospectus by reference. Any statement contained in this prospectus supplement and the accompanying prospectus or in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this prospectus supplement and the accompanying prospectus to the extent that a statement contained in any subsequently filed document which is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus supplement and the accompanying prospectus.

You may request a copy of these filings, at no cost, by writing or telephoning us at the following address or telephone number:

AtriCure, Inc.

6217 Centre Park Drive

West Chester, Ohio 45069

Attention: Secretary

Phone: (513) 755-4100

Exhibits to the filings will not be sent, unless those exhibits have been specifically incorporated by reference in this prospectus supplement and the accompanying prospectus.

Table of Contents

Prospectus

\$150,000,000
Common Stock, Preferred Stock, Debt Securities, Warrants,
Depository Shares and Units
and
3,258,133 Shares of Common Stock

By this prospectus and an accompanying prospectus supplement, we may from time to time offer and sell, in one or more offerings, up to \$150,000,000 in any combination of common stock, preferred stock, debt securities, warrants, depository shares and units. Also, selling securityholders identified in this prospectus may, from time to time, offer and sell up to an additional 3,258,133 shares of common stock. See **Selling Securityholders**.

We will provide you with more specific terms of these securities in one or more supplements to this prospectus. You should read this prospectus and the applicable prospectus supplement carefully before you invest.

We or any selling securityholders may offer these securities from time to time in amounts, at prices and on other terms to be determined at the time of offering. We or any selling securityholders may offer and sell these securities to or through underwriters, dealers or agents, or directly to investors, on a continuous or delayed basis. The supplements to this prospectus will provide the specific terms of the plan of distribution. The price to the public of such securities and the net proceeds we expect to receive from such sale will also be set forth in a prospectus supplement.

Our common stock is listed on the NASDAQ Global Market under the symbol **ATRC**.

On February 4, 2014, the closing price of our common stock as reported by the NASDAQ Global Market was \$20.90 per share.

Investing in our securities involves risks. See Risk Factors beginning on page 5.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus. Any representation

to the contrary is a criminal offense.

The date of this prospectus is February 6, 2014

Table of Contents**TABLE OF CONTENTS**

	Page
<u>ABOUT THIS PROSPECTUS</u>	2
<u>WHERE YOU CAN FIND MORE INFORMATION</u>	3
<u>INFORMATION INCORPORATED BY REFERENCE</u>	3
<u>RISK FACTORS</u>	5
<u>SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS</u>	6
<u>ATRICURE, INC.</u>	6
<u>RECENT DEVELOPMENTS</u>	7
<u>USE OF PROCEEDS</u>	7
<u>RATIO OF EARNINGS TO FIXED CHARGES</u>	7
<u>DESCRIPTION OF THE SECURITIES WE MAY OFFER</u>	7
<u>DESCRIPTION OF COMMON STOCK</u>	8
<u>DESCRIPTION OF PREFERRED STOCK</u>	10
<u>DESCRIPTION OF DEBT SECURITIES</u>	12
<u>DESCRIPTION OF WARRANTS</u>	18
<u>DESCRIPTION OF DEPOSITARY SHARES</u>	19
<u>ISSUANCE OF COMMON STOCK PURSUANT TO OUR ACQUISITION OF ESTECH</u>	22
<u>SELLING SECURITYHOLDERS</u>	22
<u>PLAN OF DISTRIBUTION</u>	25
<u>LEGAL MATTERS</u>	26
<u>EXPERTS</u>	26
<u>FINANCIAL STATEMENTS</u>	F-1

ABOUT THIS PROSPECTUS

This prospectus is part of a registration statement filed with the Securities and Exchange Commission using a shelf registration process. Under this shelf process, we or any selling securityholders may sell the securities described in this prospectus in one or more offerings. This prospectus provides you with a general description of the securities which may be offered. Each time securities are offered for sale, we will provide a prospectus supplement that contains specific information about the terms of that offering. The prospectus supplement may also add or update information contained in this prospectus. You should read both this prospectus and any prospectus supplement together with additional information described below under **Where You Can Find More Information** and **Information Incorporated by Reference**.

The registration statement that contains this prospectus (including the exhibits thereto) contains additional important information about us and the selling securityholders and the securities we or any selling securityholders may offer under this prospectus. Specifically, we have filed certain legal documents that establish the terms of the securities offered by this prospectus as exhibits to the registration statement. We will file certain other legal documents that establish the terms of the securities offered by this prospectus as exhibits to reports we file with the SEC. You may obtain copies of that registration statement and the other reports and documents referenced herein as described below under the heading **Where You Can Find More Information**.

You should rely only on the information contained or incorporated by reference in this prospectus and in any prospectus supplement. We have not authorized any other person to provide you with different information. If anyone provides you with different or inconsistent information, you should not rely on it. We are not making offers to sell or solicitations to buy the securities in any jurisdiction in which an offer or solicitation is not authorized or in which the person making that offer or solicitation is not qualified to do so or to anyone to whom it is unlawful to make an offer or solicitation. You should not assume that the information in this prospectus or any prospectus supplement, as well as the information we file or previously filed with the SEC that we incorporate by reference in this prospectus or any prospectus supplement, is accurate as of any date other than its respective date. Our business, financial condition, results of operations and prospects may have changed since those dates.

In this prospectus, unless the context otherwise requires, references to we, us, our or AtriCure refer to AtriCure, Inc. and its subsidiaries.

Table of Contents

WHERE YOU CAN FIND MORE INFORMATION

We file annual, quarterly and other reports, proxy statements and other information with the SEC. Our SEC filings are available to the public over the Internet at the SEC's website at <http://www.sec.gov>. You may also read and copy any document we file at the SEC's Public Reference Room at 100 F Street, NE, Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the operation of the Public Reference Room. Our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, including any amendments to those reports, and other information that we file with or furnish to the SEC pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the Exchange Act) can also be accessed free of charge through the Internet.

We have filed with the SEC a registration statement under the Securities Act of 1933 relating to the offering of these securities. The registration statement, including the attached exhibits, contains additional relevant information about us, and the selling securityholders and the securities. This prospectus does not contain all of the information set forth in the registration statement. You can obtain a copy of the registration statement from the SEC as described above. The registration statement and the documents referred to below under "Information Incorporated by Reference" and our other SEC filings are also available on our Internet website, <http://www.atricure.com>. We have not incorporated by reference into this prospectus the information on our website, and you should not consider it to be a part of this prospectus.

INFORMATION INCORPORATED BY REFERENCE

The SEC allows us to incorporate by reference into this prospectus certain information we file with it, which means that we can disclose important information by referring you to those documents. The information incorporated by reference is considered to be a part of this prospectus, and information that we file later with the SEC will automatically update and supersede information contained in this prospectus and any accompanying prospectus supplement. We incorporate by reference the documents listed below that we have previously filed with the SEC (excluding any portions of any Form 8-K that are not deemed filed pursuant to the General Instructions of Form 8-K):

our Annual Report on Form 10-K for the year ended December 31, 2012;

our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2013, June 30, 2013 and September 30, 2013;

our Current Reports on Form 8-K filed on January 16, 2013, January 31, 2013, March 11, 2013, March 29, 2013, May 24, 2013, September 3, 2013, December 19, 2013, January 2, 2014 and January 9, 2014 (excluding any information furnished in such reports under Item 2.02, Item 7.01 or Item 9.01); and

the description of our common stock contained in our Registration Statement on Form 8-A as filed with the SEC on or about August 1, 2005.

We also incorporate by reference into this prospectus additional documents that we may file with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act prior to the completion or termination of the offering, including all such documents we may file with the SEC after the date of the initial registration statement and prior to the

effectiveness of the registration statement, but excluding any information deemed furnished and not filed with the SEC. Any statements contained in a previously filed document incorporated by reference into this prospectus is deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained in this prospectus, or in a subsequently filed document also incorporated by reference herein, modifies or supersedes that statement.

Table of Contents

This prospectus may contain information that updates, modifies or is contrary to information in one or more of the documents incorporated by reference in this prospectus. You should rely only on the information incorporated by reference or provided in this prospectus. We have not authorized anyone else to provide you with different information. You should not assume that the information in this prospectus is accurate as of any date other than the date of this prospectus or the date of the documents incorporated by reference in this prospectus.

We will provide to each person, including any beneficial owner, to whom this prospectus is delivered, upon written or oral request, at no cost to the requester, a copy of any and all of the information that is incorporated by reference in this prospectus.

Requests for such documents should be directed to:

Investor Relations

AtriCure, Inc.

6217 Centre Park Drive

West Chester, Ohio 45069

Telephone: (513) 755-4100

You may also access the documents incorporated by reference in this prospectus through our website at <http://www.atricure.com>. Except for the specific incorporated documents listed above, no information available on or through our website shall be deemed to be incorporated in this prospectus or the registration statement of which it forms a part.

Table of Contents

RISK FACTORS

Investing in our securities involves risk. Please see the risk factors set forth below and in Part I, Item 1A in our Annual Report on Form 10-K for our most recent fiscal year, as updated by our quarterly reports on Form 10-Q and other filings we make with the SEC, as incorporated by reference in this prospectus. Additional risk factors may be included in a prospectus supplement relating to a particular series or offering of securities. Before making an investment decision, you should carefully consider these risks as well as other information we include or incorporate by reference in this prospectus. The risks and uncertainties we have described are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also affect our business operations. These risks could materially affect our business, results of operations or financial condition and cause the value of our securities to decline.

Our business growth strategy involves the potential for significant acquisitions, which involve risks and difficulties in integrating potential acquisitions and may adversely affect our business, results of operations and financial condition.

All acquisitions involve inherent uncertainties, which may include, among other things, our ability to:

successfully identify targets for acquisition;

negotiate reasonable terms;

properly perform due diligence and determine all the significant risks associated with a particular acquisition;

properly evaluate target company management capabilities; and

successfully transition the acquired company into our business and achieve the desired performance.

We may acquire businesses with unknown liabilities, contingent liabilities, or internal control deficiencies. We have plans and procedures to conduct reviews of potential acquisition candidates for compliance with applicable regulations and laws prior to acquisition. Despite these efforts, realization of any of these liabilities or deficiencies may increase our expenses, adversely affect our financial position through the initiation, pendency or outcome of litigation or otherwise, or cause us to fail to meet our public financial reporting obligations.

We have recently consummated a significant acquisition, and in the future may continue to invest a substantial amount of capital in acquisitions. We continue to evaluate potential acquisition opportunities to support, strengthen and grow our business. There can be no assurance that we will be able to locate suitable acquisition candidates, acquire possible acquisition candidates, acquire such candidates on commercially reasonable terms, or integrate acquired businesses successfully in the future. In addition, any governmental review or investigation of our proposed acquisitions, such as by the Federal Trade Commission, may impede, limit or prevent us from proceeding with an acquisition. Future acquisitions may require us to incur additional debt and contingent liabilities, which may adversely affect our business, results of operations and financial condition. The process of integrating acquired businesses into our existing

operations may result in operating, contract and supply chain difficulties, such as the failure to retain customers or management personnel. Such difficulties may divert significant financial, operational and managerial resources from our existing operations, and make it more difficult to achieve our operating and strategic objectives.

We may not realize the anticipated benefits of recent acquisitions.

Our expectations regarding the earnings, operating cash flow, capital expenditures and liabilities resulting from acquisitions are based on information currently available to us and may prove to be incorrect. Our inability to realize any of the anticipated benefits of an acquisition and to successfully integrate the acquired assets into our existing business will have an adverse effect on our financial condition.

Table of Contents

SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS

This prospectus (including the information incorporated by reference) contains certain statements that may be deemed to be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements anticipate results based on our estimates, assumptions and plans that are subject to uncertainty. The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements. All statements in this prospectus and any accompanying prospectus supplement not dealing with historical results or current facts are forward-looking and are based on estimates, assumptions and projections. Statements which include the words believes, seeks, expects, may, should, intend, likely, targets, plans, anticipates, estimates or the negative version of those words and similar statements of a forward-looking nature identify forward-looking statements.

Factors that could cause actual results to differ from those in the forward-looking statements may accompany the statements themselves. In addition, generally applicable factors that could cause actual results or outcomes to differ from those expressed in the forward-looking statements are and will be discussed in our reports on Forms 10-K, 10-Q and 8-K incorporated by reference in this prospectus.

All forward-looking statements address matters that involve risks and uncertainties. Accordingly, there are or will be important factors that could cause actual results to differ materially from those indicated in these statements. These risks and uncertainties include the rate and degree of market acceptance of AtriCure's products, AtriCure's ability to develop and market new and enhanced products, the timing of and ability to obtain and maintain regulatory clearances and approvals for its products, the timing of and ability to obtain reimbursement of procedures utilizing AtriCure's products, AtriCure's ability to consummate acquisitions or, if consummated, to successfully integrate acquired businesses into AtriCure's operations, AtriCure's ability to recognize the benefits of acquisitions, including potential synergies and cost savings, failure of an acquisition or acquired company to achieve its plans and objectives generally, risk that proposed or consummated acquisitions may disrupt operations or pose difficulties in employee retention or otherwise affect financial or operating results, competition from existing and new products and procedures or AtriCure's ability to effectively react to other risks and uncertainties described from time to time in AtriCure's SEC filings, such as fluctuation of quarterly financial results, reliance on third party manufacturers and suppliers, litigation or other proceedings, government regulation and stock price volatility. We do not undertake any obligation to publicly update or review any forward-looking statement.

ATRICURE, INC.

AtriCure, Inc. is a medical device company providing innovative atrial fibrillation (Afib) solutions designed to produce superior outcomes that reduce the economic and social burden of atrial fibrillation. AtriCure's Synergy Ablation System is the first and only device approved for the treatment of Persistent and Longstanding Persistent forms of Afib in patients undergoing certain open concomitant procedures. AtriCure's AtriClip Left Atrial Appendage (LAA) exclusion device is the most widely implanted device for LAA management worldwide. The company believes cardiothoracic surgeons are adopting its ablation and LAA management devices for the treatment of Afib and reduction of Afib related complications such as stroke. Afib affects more than 5.5 million people worldwide.

We were incorporated in the State of Delaware as AtriCure, Inc. on October 31, 2000. Our principal executive offices are located at 6217 Centre Park Drive, West Chester, Ohio 45069. Our telephone number is (513) 755-4100. SEC filings, news releases, our Code of Ethics applicable to directors, officers and employees and other information may be accessed free of charge through our Internet website at <http://www.atricure.com>. Other than the information specifically incorporated by reference in this prospectus, information on our website is not part of this prospectus.

Table of Contents**RECENT DEVELOPMENTS**

On December 31, 2013 AtriCure acquired Endoscopic Technologies, Inc. d/b/a/Estech (Estech) pursuant to a Merger Agreement in which AtriCure agreed to pay \$34 million in shares of common stock and up to \$26 million in additional consideration based on the achievement of certain performance based milestones. Estech, a privately held company based in San Ramon, California, develops and markets a broad portfolio of innovative medical devices and disposables that enable cardiac surgeons to perform a variety of traditional and minimally invasive surgical procedures.

USE OF PROCEEDS

Unless otherwise indicated in an accompanying prospectus supplement, we expect to use the net proceeds from the sale of any securities offered by us for general corporate purposes, which may include the repayment of outstanding debt. Until the net proceeds are used for these purposes, we may deposit them in interest-bearing accounts or invest them in marketable securities. The specific allocations, if any, of the proceeds from the sale of any of the securities will be described in the prospectus supplement relating to the offering of the securities.

Unless otherwise indicated in a prospectus supplement, we will not receive any proceeds from the sale of securities by any selling securityholder.

RATIO OF EARNINGS TO FIXED CHARGES

The following table sets forth our ratio of earnings to fixed charges for the periods indicated:

	Fiscal Years					
	Nine Months ended September 30,					
	2013	2012	2011	2010	2009	2008
Ratio of earnings to fixed charges	N/A	N/A	N/A	N/A	N/A	N/A

Ratio of earnings to fixed charges is not applicable as the Company is deficient in earnings by \$5,884, \$6,485, \$4,442, \$2,754, \$15,581, and \$9,719 for the nine months ended September 30, 2013 and fiscal years ending 2012, 2011, 2010, 2009, and 2008, respectively.

DESCRIPTION OF THE SECURITIES WE MAY OFFER

We may issue, in one or more offerings, any combination of common stock, preferred stock, debt securities, warrants, depositary shares and units.

This prospectus contains a summary of the general terms of the various securities that we may offer. The prospectus supplement relating to any particular securities offered will describe the specific terms of the securities. The summary in this prospectus and in any prospectus supplement does not describe every aspect of the securities and is subject to and qualified in its entirety by reference to all applicable provisions of the documents relating to the securities offered. These documents are or will be filed as exhibits to or incorporated by reference in the registration statement.

In addition, the prospectus supplement will set forth the terms of the offering, the initial public offering price and net proceeds to us. Where applicable, the prospectus supplement will also describe any material United States federal income tax considerations relating to the securities offered and indicate whether the securities offered are or will be listed on any securities exchange.

Table of Contents

DESCRIPTION OF COMMON STOCK

This section summarizes the general terms of the common stock that we may offer. The prospectus supplement relating to the common stock offered will set forth the number of shares offered, the initial offering price and recent market prices, dividend information and any other relevant information. The summary in this section and in the prospectus supplement does not describe every aspect of the common stock and is subject to and qualified in its entirety by reference to all the provisions of our Amended and Restated Certificate of Incorporation and Second Amended and Restated Bylaws and to the provisions of the Delaware General Corporate Law.

The following briefly summarizes the material terms of the common stock that we may offer, other than pricing and related terms which will be disclosed in a prospectus supplement. The total number of authorized shares of common stock is 90,000,000, par value \$0.001 per share. Holders of common stock are entitled to one vote for each share held of record on all matters submitted to a vote of shareholders. Shareholders do not have the right to cumulate their votes in the election of directors. Our board of directors is authorized to issue the shares of common stock that are authorized but not yet issued without further shareholder approval.

Holders of common stock are entitled to receive dividends when and if declared by our board of directors out of funds legally available therefor, subject to any contractual restrictions on the payment of dividends and to any restrictions on the payment of dividends imposed by the terms of any outstanding preferred shares or debt securities.

Upon our dissolution or liquidation or the sale of all or substantially all of our assets, after payment in full of all amounts required to be paid to creditors and to the holders of preferred shares having liquidation preferences, if any, the holders of our common stock will be entitled to receive pro rata our remaining assets available for distribution.

As of January 31, 2014, we had 23,363,948 shares of common stock outstanding. Shares of common stock carry no preemptive or conversion or subscription rights and are not subject to redemption or sinking fund provisions. All outstanding shares of common stock are, and any shares of common stock issued upon conversion of any convertible securities or exercise of employee stock options will be, fully paid and non-assessable. Please see **Recent Developments** for information about shares of common stock that may be issued in connection with our recent acquisition.

Our common stock is listed on the NASDAQ Global Market and trades under the symbol **ATRC**. Our registrar and transfer agent is American Stock Transfer & Trust Company.

Anti-Takeover Effects of Provisions of Our Amended and Restated Certificate of Incorporation and Bylaws

Provisions of our Amended and Restated Certificate of Incorporation and Second Amended and Restated Bylaws may have the effect of making it more difficult for a third party to acquire, or of discouraging a third party from attempting to acquire, control of us. Because our shareholders do not have cumulative voting rights, our shareholders representing a majority of the shares of common stock outstanding will be able to elect all of our directors. Our Amended and Restated Certificate of Incorporation and Second Amended and Restated Bylaws provide that all shareholder action must be effected at a duly called meeting of shareholders and not by a consent in writing, and that only our board of directors, chairman of the board, chief executive officer or president (in the absence of a chief executive officer) may call a special meeting of shareholders. Our Amended and Restated Certificate of Incorporation requires a 66 2/3% shareholder vote for the amendment, repeal or modification of certain provisions of our Amended and Restated Certificate of Incorporation and Second Amended and Restated Bylaws relating to the absence of cumulative voting, limitations of liability of our directors, the requirement that shareholder actions be effected at a duly-called meeting and the designated parties entitled to call a special meeting of the shareholders.

Table of Contents

The combination of the lack of cumulative voting and the 66 2/3% shareholder voting requirement will make it more difficult for our existing shareholders to replace our board of directors as well as for another party to obtain control of us by replacing our board of directors. Since our board of directors has the power to retain and discharge our officers, these provisions could also make it more difficult for existing shareholders or another party to effect a change in management. In addition, the authorization of undesignated preferred stock makes it possible for our board of directors to issue preferred stock with voting or other rights or preferences that could impede the success of any attempt to change our control.

These provisions may have the effect of deterring hostile takeovers or delaying changes in our control or management. These provisions are intended to enhance the likelihood of continued stability in the composition of our board of directors and in the policies they implement, and to discourage certain types of transactions that may involve an actual or threatened change of our control. These provisions are designed to reduce our vulnerability to an unsolicited acquisition proposal. The provisions also are intended to discourage certain tactics that may be used in proxy fights. However, such provisions could have the effect of discouraging others from making tender offers for our shares and, as a consequence, they also may inhibit fluctuations in the market price of our shares that could result from actual or rumored takeover attempts. Such provisions may also have the effect of preventing changes in our management.

Delaware Anti-Takeover Statute

We are subject to Section 203 of the Delaware General Corporation Law. This law prohibits a publicly held Delaware corporation from engaging in any business combination with any interested shareholder for a period of three years following the date that the shareholder became an interested shareholder unless:

prior to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction that resulted in the shareholder becoming an interested shareholder;

upon consummation of the transaction which resulted in the shareholder becoming an interested shareholder, the interested shareholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the number of shares outstanding those shares owned by persons who are directors or officers or by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or

on or subsequent to the date of the transaction, the business combination is approved by the board of directors and authorized at an annual or special meeting of shareholders, and not by written consent, by the affirmative vote of at least two-thirds of the outstanding voting stock which is not owned by the interested shareholder.

Section 203 defines business combination to include:

any merger or consolidation involving the corporation and the interested shareholder;

any sale, transfer, pledge or other disposition of 10% or more of our assets involving the interested shareholder;

in general, any transaction that results in the issuance or transfer by us of any of our stock to the interested shareholder;

any transaction involving the corporation that has the effect of increasing the proportionate share of the stock or any class or series of the corporation beneficially owned by the interested shareholder; or

the receipt by the interested shareholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation.

Table of Contents

In general, Section 203 defines an interested shareholder as an entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by the entity or person.

DESCRIPTION OF PREFERRED STOCK

The following briefly summarizes the material terms of the preferred stock that we may offer, other than pricing and related terms which will be disclosed in a prospectus supplement. You should read the particular terms of any series of preferred stock that we offer, which we will describe in more detail in any prospectus supplement relating to such series. You should also read the more detailed provisions of our Articles of Incorporation and the statement with respect to shares relating to each particular series of preferred stock for provisions that may be important to you. The statement with respect to shares relating to each particular series of preferred stock offered by the accompanying prospectus supplement and this prospectus will be filed as an exhibit to a document incorporated by reference in the registration statement. The prospectus supplement will also state whether any of the terms summarized below do not apply to the series of preferred stock being offered.

General

Our board of directors is authorized to issue up to 10,000,000 shares of preferred stock, par value \$0.001 per share. As of the date of this prospectus, we have not issued any shares of preferred stock. Our board of directors can issue shares of preferred stock in one or more series and can specify the following terms for each series:

the number of shares;

the designation, powers, preferences and rights of the shares; and

the qualifications, limitations or restrictions, except as otherwise stated in our Amended and Restated Certificate of Incorporation.

Before issuing any series of preferred stock, our board of directors will adopt resolutions creating and designating the series as a series of preferred stock, and the resolutions will be filed in a statement with respect to shares as an amendment to our Amended and Restated Certificate of Incorporation.

The rights of holders of the preferred stock offered may be adversely affected by the rights of holders of any shares of preferred stock that may be issued in the future. Our board of directors may cause shares of preferred stock to be issued in public or private transactions for any proper corporate purpose. Examples include issuances to obtain additional financing in connection with acquisitions or otherwise, and issuances to our officers, directors and employees and its subsidiaries pursuant to benefit plans or otherwise. The preferred stock could have the effect of acting as an anti-takeover device to prevent a change in control of us.

Unless the particular prospectus supplement states otherwise, holders of each series of preferred stock will not have any preemptive or subscription rights to acquire more of our stock.

The transfer agent, registrar, dividend disbursing agent and redemption agent for shares of each series of preferred stock will be named in the prospectus supplement relating to such series.

Rank

Unless otherwise specified in the prospectus supplement relating to the shares of any series of preferred stock, the shares will rank on an equal basis with each other series of preferred stock and prior to the common stock as to dividends and distributions of assets.

Table of Contents

Dividends

Unless the particular prospectus supplement states otherwise, holders of each series of preferred stock will be entitled to receive cash dividends, when, as and if declared by our board of directors out of funds legally available for dividends. The rates and dates of payment of dividends will be set forth in the prospectus supplement relating to each series of preferred stock. Dividends will be payable to holders of record of preferred stock as they appear on our books. Dividends on any series of preferred stock may be cumulative or noncumulative.

We may not declare, pay or set apart for payment dividends on the preferred stock unless full dividends on any other series of preferred stock that ranks on an equal or senior basis have been paid or sufficient funds have been set apart for payment for:

all prior dividend periods of the other series of preferred stock that pay dividends on a cumulative basis; or

the immediately preceding dividend period of the other series of preferred stock that pay dividends on a noncumulative basis.

Partial dividends declared on shares of preferred stock and any other series of preferred stock ranking on an equal basis as to dividends will be declared pro rata. A pro rata declaration means that the ratio of dividends declared per share to accrued dividends per share will be the same for all such series of preferred stock.

Similarly, we may not declare, pay or set apart for payment non-stock dividends or make other payments on the common stock or any other stock ranking junior to the preferred stock unless full dividends on all series of preferred stock have been paid or set apart for payment for:

all prior dividend periods if the preferred stock pays dividends on a cumulative basis; or

the immediately preceding dividend period if the preferred stock pays dividends on a noncumulative basis.

Conversion and Exchange

The prospectus supplement for any series of preferred stock will state the terms, if any, on which shares of that series are convertible into or exchangeable for shares of our common stock.

Redemption

If so specified in the applicable prospectus supplement, a series of preferred stock may be redeemable at any time, in whole or in part, at our option or at the option of the holders, or may be mandatorily redeemed.

Any partial redemptions of preferred stock will be made in a way that our board of directors decides is equitable.

Unless we default in the payment of the redemption price, dividends will cease to accrue after the redemption date on shares of preferred stock called for redemption and all rights of holders of such shares will terminate except for the right to receive the redemption price.

Liquidation Preference

Upon our voluntary or involuntary liquidation, dissolution or winding up, holders of each series of preferred stock will be entitled to receive distributions upon liquidation in the amount set forth in the prospectus supplement relating to such series of preferred stock, plus an amount equal to any accrued and unpaid dividends. Such distributions will be made before any distribution is made on any securities ranking junior to the preferred stock with respect to liquidation, including common stock.

Table of Contents

If the liquidation amounts payable relating to the preferred stock of any series and any other securities ranking on a parity regarding liquidation rights are not paid in full, the holders of the preferred stock of such series and such other securities will share in any such distribution of our available assets on a ratable basis in proportion to the full liquidation preferences. Holders of such series of preferred stock will not be entitled to any other amounts from us after they have received their full liquidation preference.

Voting Rights

If we issue voting such preferred stock, holders of preferred stock will be entitled to one vote per share on each matter submitted to our shareholders. If we issue non-voting such preferred stock, holders of preferred stock will have no voting rights, except as required by applicable law. The prospectus supplement will state the voting rights, if any, applicable to any particular series of preferred stock.

DESCRIPTION OF DEBT SECURITIES

General

The debt securities are governed by documents called indentures. An indenture is a contract between AtriCure and the trustee named in the applicable prospectus supplement, which acts as trustee for the debt securities. There may be more than one trustee under each indenture for different series of debt securities. The trustee has two main roles. First, the trustee can enforce your rights against AtriCure if AtriCure defaults. There are some limitations on the extent to which the trustee acts on your behalf, described under Remedies If An Event of Default Occurs. Second, the trustee may perform administrative duties for AtriCure, such as sending you interest payments, transferring your debt securities to a new buyer if you sell, and sending you notices.

The debt securities will be unsecured general obligations of AtriCure and may include:

senior debt securities, to be issued under the senior indenture; and

subordinated debt securities, to be issued under the subordinated indenture.

The prospectus supplement relating to any particular debt securities offered will indicate whether the debt securities are senior debt securities or subordinated debt securities and will describe the specific terms of the debt securities. The summary in this section and in any prospectus supplement does not describe every aspect of the senior or subordinated indenture or the debt securities, and is subject to and qualified in its entirety by reference to all the provisions of the applicable indenture and the debt securities. The forms of the senior indenture and subordinated indenture and the forms of the debt securities are or will be filed as exhibits to or incorporated by reference in the registration statement. See [Where You Can Find More Information](#) for information on how to obtain a copy.

This section summarizes the general terms of the senior and subordinated debt securities that we may offer. When we refer to the indenture, we mean the senior indenture and the subordinated indenture collectively, unless we indicate otherwise. When we refer to the trustee, we mean the senior trustee and the subordinated trustee collectively, unless we indicate otherwise. When we refer to the debt securities, we mean the senior and subordinated debt securities, unless we indicate otherwise.

The prospectus supplement relating to any series of debt securities will describe the following specific financial, legal and other terms particular to such series of debt securities:

the title of the debt securities;

any limit on the aggregate principal amount of the debt securities;

the date or dates on which the debt securities will mature;

Table of Contents

the rate or rates (which may be fixed or variable) at which the debt securities will bear interest, if any, and the date or dates from which the interest will accrue;

the dates on which interest on the debt securities will be payable and the regular record dates for those interest payment dates;

the place or places where the principal and premium, if any, and interest, if any, shall be payable, where the debt securities may be surrendered for transfer or exchange, and where notices and demands may be served;

the date, if any, after which and the price or prices at which the debt securities may, in accordance with any option or mandatory redemption provisions, be redeemed and the other detailed terms and provisions of any such optional or mandatory redemption provision;

any mandatory or optional sinking funds or analogous provisions or provisions for redemption at the holder's option;

the denomination in which the debt securities will be issuable, if other than denominations of \$1,000 and any integral multiple thereof;

if other than the principal amount thereof, the portion of the principal amount of the debt securities which will be payable upon the declaration of acceleration of the maturity of those debt securities;

any addition to, or modification or deletion of, any events of default or covenants with respect to the securities;

any provision relating to the defeasance of our obligations in connection with the debt securities;

any provision regarding exchangeability or conversion of the debt securities into our common stock or other securities;

whether any debt securities will be issued in the form of a global security, and, if different than described below under "Book-Entry Securities," any circumstances under which a global security may be exchanged for debt securities registered in the names of persons other than the depository for the global security or its nominee;

the subordination provisions applicable to the subordinated debt securities; and

any other material terms of the debt securities.

The terms of any series of debt securities may vary from the terms described here. Thus, this summary also is subject to and qualified by reference to the description of the particular terms of your debt securities to be described in the prospectus supplement. The prospectus supplement relating to the debt securities will be attached to the front of this prospectus.

The indenture and its associated documents contain the full legal text of the matters described in this section. The indenture and the debt securities are governed by New York law.

Events Of Default

You will have special rights if an event of default occurs, with respect to any series of debt securities, and is not cured, as described later in this subsection. Under the indenture, the term event of default means any of the following:

AtriCure does not pay interest on a debt security within 30 days of its due date;

AtriCure does not pay the principal or any premium on a debt security on its due date;

Table of Contents

AtriCure remains in breach of any covenant or warranty described in the indenture for 90 days after AtriCure receives a notice stating it is in breach, which notice must be sent by either the trustee or direct holders of at least 25% of the principal amount of outstanding debt securities;

AtriCure fails to pay an amount of debt as defined in any mortgage, indenture, security agreement or other instrument totaling more than \$25,000,000 in principal amount, AtriCure's obligation to repay is accelerated by its lenders, and this payment obligation remains accelerated for 30 days after AtriCure receives notice of default as described in the previous paragraph;

AtriCure becomes subject to one or more final, non-appealable judgments, orders or decrees requiring payments of more than \$25,000,000 and such judgments, orders or decrees remain unsatisfied for 60 days during which a stay of enforcement has not been in effect after AtriCure receives notice as described two paragraphs above; or

certain events of bankruptcy, insolvency or reorganization of AtriCure.

Remedies if an Event of Default Occurs

If an event of default has occurred and has not been cured (if a cure period is provided for), the trustee or the direct holders of 25% in principal amount of the outstanding debt securities may declare the entire principal amount of all the debt securities of that series to be due and immediately payable. This is called a declaration of acceleration of maturity.

Except in cases of default, whereby a trustee has some special duties, a trustee is not required to take any action under the indenture at the request of any direct holders unless the direct holders offer the trustee reasonable protection from costs, expenses and liability (called an indemnity). If reasonable indemnity is provided, the direct holders of a majority in principal amount of the outstanding debt securities of the relevant series may direct the time, method and place of conducting any lawsuit or other formal legal action seeking any remedy available to the trustee. These majority direct holders may also direct the trustee in performing any other action under the indenture.

In general, before you bypass the trustee and bring your own lawsuit or other formal legal action or take other steps to enforce your rights or protect your interests relating to the debt securities, the following must occur:

you must give the trustee written notice that an event of default has occurred and remains uncured;

the direct holders of at least 25% in principal amount of all outstanding debt securities of the relevant series must make a written request that the trustee take action in its own name as trustee because of the default, and must offer reasonable indemnity to the trustee against the costs, expenses and other liabilities of taking that action;

the trustee must have not taken action for 60 days after receipt of the above notice and offer of indemnity;
and

the trustee must not have received from direct holders of a majority in principal amount of the outstanding debt securities of that series a direction inconsistent with the written notice during the 60 day period after receipt of the above notice.

However, you are entitled at any time to bring a lawsuit for the payment of money due on your debt security on or after its due date.

Modification

There are three types of changes we can make to the indentures and the debt securities.

Table of Contents

Changes Requiring Your Approval

First, there are changes that cannot be made to the indentures or your debt securities without your specific approval. The following is a list of those types of changes:

change the payment due date;

reduce any amounts due on a debt security;

reduce the amount of principal payable upon acceleration of the maturity of a debt security following a default;

impair your right to sue for payment;

reduce the percentage in principal amount of debt securities, the consent of whose holders is required to modify or amend the indenture;

reduce the percentage in principal amount of debt securities, the consent of whose holders is required to waive compliance with certain provisions of the indenture or to waive certain defaults; and

modify any other aspect of the provisions dealing with modification and waiver of the indenture.

Changes Requiring a Majority Vote

The second type of change to the indentures and the debt securities is the kind that requires consent of the holders of a majority in principal amount of the outstanding debt securities of the particular series affected. With a majority vote, the holders may waive past defaults, provided that such defaults are not of the type described previously under Changes Requiring Your Approval.

Changes Not Requiring Approval

The third type of change does not require any vote by direct holders of debt securities. This type is limited to clarifications and certain other changes that would not adversely affect holders of the debt securities.

Consolidation, Merger And Sale Of Assets

AtriCure may consolidate or merge with or into another entity, and AtriCure may sell or lease substantially all of AtriCure's assets to another corporation if the following conditions, among others, are met:

where AtriCure merges out of existence or sells or leases substantially all its assets, the other entity must be a corporation, partnership or trust organized under the laws of a state or the District of Columbia or under federal law, and it must agree to be legally responsible for the debt securities; and

the merger, sale of assets or other transaction must not cause a default or an event of default on the debt securities.

Form, Exchange, Registration And Transfer

Generally, we will issue debt securities only in registered global form. See **Book-Entry Securities** below. However, if specified in the prospectus supplement, we may issue certificated securities in definitive form.

You may have your debt securities broken into more debt securities of smaller denominations or combined into fewer debt securities of larger denominations, as long as the total principal amount is not changed. This is called an exchange.

Table of Contents

You may exchange or transfer debt securities at the office of the trustee. The trustee acts as our agent for registering debt securities in the names of holders and transferring debt securities. We may appoint another entity or perform this role itself. The entity performing the role of maintaining the list of registered direct holders is called the security registrar. It will also perform transfers. You will not be required to pay a service charge to transfer or exchange debt securities, but you may be required to pay for any tax or other governmental charge associated with the exchange or transfer. The transfer or exchange will only be made if the security registrar is satisfied with your proof of ownership.

If the debt securities are redeemable and AtriCure redeems less than all of the debt securities of a particular series, AtriCure may block the transfer or exchange of those debt securities during the period beginning 15 days before the day AtriCure mails the notice of redemption and ending on the day of that mailing, in order to freeze the list of holders to prepare the mailing. We may also refuse to register transfers or exchanges of debt securities selected for redemption, except that we will continue to permit transfers and exchanges of the unredeemed portion of any debt security being partially redeemed.

Book-Entry Securities

The debt securities will be represented by one or more global securities. Unless otherwise indicated in the prospectus supplement, the global security representing the debt securities will be deposited with, or on behalf of, The Depository Trust Company (DTC), New York, New York, or other successor depository we appoint, and registered in the name of the depository or its nominee. The debt securities will not be issued in definitive form unless otherwise provided in the prospectus supplement.

DTC will act as securities depository for the securities. The debt securities will be issued as fully registered securities registered in the name of Cede & Co. (DTC's nominee).

DTC has informed us as follows:

DTC is a limited-purpose trust company organized under the New York Banking Law, a banking organization within the meaning of the New York Banking Law, a member of the Federal Reserve System, a clearing corporation within the meaning of the New York Uniform Commercial Code, and a clearing agency registered pursuant to the provisions of Section 17A of the Securities Exchange Act of 1934.

DTC holds securities that its participants deposit with DTC and facilitates the settlement among participants of securities transactions, such as transfers and pledges, in deposited securities through electronic computerized book-entry changes in participants' accounts, thereby eliminating the need for physical movement of securities certificates.

Direct participants include securities brokers and dealers, trust companies, clearing corporations, and certain other organizations.

DTC is owned by a number of its direct participants and by the New York Stock Exchange, Inc., the American Stock Exchange, Inc. and the Financial Industry Regulatory Authority.

Access to the DTC system is also available to indirect participants such as securities brokers and dealers, banks and trust companies that clear through or maintain a custodial relationship with a direct participant, either directly or indirectly.

The rules applicable to DTC and its direct and indirect participants are on file with the SEC. We have provided the following descriptions of the operations and procedures of DTC solely as a matter of convenience. These operations and procedures are solely within the control of DTC and are subject to change by them from time to time. Neither we, any underwriter nor the trustee take any responsibility for these operations or procedures, and you are urged to contact DTC or its participants directly to discuss these matters.

Table of Contents

We expect that under procedures established by DTC:

Upon deposit of the global securities with DTC or its custodian, DTC will credit on its internal system the accounts of direct participants designated by the underwriters with portions of the principal amounts of the global securities; and

Ownership of the debt securities will be shown on, and the transfer of ownership of the debt securities will be effected only through, records maintained by DTC or its nominee, with respect to interests of direct participants, and the records of direct and indirect participants, with respect to interests of persons other than participants.

The laws of some jurisdictions require that purchasers of securities take physical delivery of those securities in the form of a certificate. For that reason, it may not be possible to transfer interests in a global security to those persons. In addition, because DTC can act only on behalf of its participants, who in turn act on behalf of persons who hold interests through participants, the ability of a person having an interest in a global security to pledge or transfer that interest to persons or entities that do not participate in DTC's system, or otherwise to take actions in respect of that interest, may be affected by the lack of a physical definitive security in respect of that interest.

So long as DTC or its nominee is the registered owner of a global security, DTC or that nominee will be considered the sole owner or holder of the debt securities represented by that global security for all purposes under the mortgage indenture and under the debt securities. Except as described below, owners of beneficial interests in a global security will not be entitled to have debt securities represented by that global security registered in their names, will not receive or be entitled to receive the debt securities in the form of a physical certificate and will not be considered the owners or holders of the debt securities under the mortgage indenture or under the debt securities, and may not be entitled to give the trustee directions, instructions or approvals. For that reason, each holder owning a beneficial interest in a global security must rely on DTC's procedures and, if that holder is not a direct or indirect participant in DTC, on the procedures of the DTC participant through which that holder owns its interest, to exercise any rights of a holder of debt securities under the mortgage indenture or the global security.

We will not have any responsibility or liability for any aspect of DTC's records relating to the debt securities or relating to payments made by DTC on account of the debt securities, or any responsibility to maintain, supervise or review any of DTC's records relating to the debt securities.

We will make payments on the debt securities represented by the global securities to DTC or its nominee, as the registered owner of the debt securities. We expect that when DTC or its nominee receives any payment on the debt securities represented by a global security, DTC will credit participants' accounts with payments in amounts proportionate to their beneficial interests in the global security as shown in DTC's records. We also expect that payments by DTC's participants to owners of beneficial interests in the global security held through those participants will be governed by standing instructions and customary practice as is now the case with securities held for the accounts of customers registered in the names of nominees for such customers. DTC's participants will be responsible for those payments.

Payments on the debt securities represented by the global securities will be made in immediately available funds. Transfers between participants in DTC will be made in accordance with DTC's rules and will be settled in immediately available funds.

Notices

Notices to holders of debt securities will be given by mail to the addresses of such holders as they appear in the security register.

The Trustee

U.S. Bank National Association acts as trustee under each of the senior debt indenture and the subordinated debt indenture.

Table of Contents

DESCRIPTION OF WARRANTS

We may issue warrants for the purchase of common stock, debt securities or other securities registered pursuant to this registration statement and described in this prospectus. We may issue warrants independently or together with other securities that may be attached to or separate from the warrants. We will issue each series of warrants under a separate warrant agreement that will be entered into between us and a bank or trust company, as warrant agent, and will be described in the prospectus supplement relating to the particular issue of warrants. The warrant agent will act solely as our agent in connection with the warrant of such series and will not assume any obligation or relationship of agency for or with holders or beneficial owners of warrants. The following describes certain general terms and provisions of debt warrants or common stock warrants we may offer. We will set forth further terms of the debt warrants, common stock warrants or warrants to purchase other securities and the applicable warrant agreement in the applicable prospectus supplement.

Common Stock and Preferred Stock Warrants

The applicable prospectus supplement will describe the terms of any common stock or preferred stock warrants, including the following:

the title of such warrants;

the offering price of such warrants, which we may distribute proportionately free of charge to our shareholders (in the applicable prospectus supplement, we may refer to warrants distributed proportionately free of charge to our shareholders as rights to purchase our common stock and any securities not taken by our shareholders may be reoffered to the public);

the aggregate number of such warrants;

the designation and terms of the securities purchasable upon exercise of such warrants;

if applicable, the designation and terms of the securities with which such warrants are issued and the number of such warrants issued with each such security;

if applicable, the date from and after which such warrants and any securities issued therewith will be separately transferable;

the number of shares of securities purchasable upon exercise of the warrants and the price at which such shares may be purchased upon exercise;

the date on which the right to exercise such warrants shall commence and the date on which such right shall expire;

if applicable, the minimum or maximum amount of such warrants which may be exercised at any one time;

the currency, currencies or currency units in which the offering price, if any, and the exercise price are payable;

if applicable, a discussion of certain United States federal income tax considerations;

the identity of the warrant agent for the warrants; and

the antidilution provisions of the warrants, if any.

Debt Warrants

The applicable prospectus supplement will describe the terms of any debt warrants, including the following:

the title of the debt warrants;

the offering price for the debt warrants;

the aggregate number of the debt warrants;

Table of Contents

the designation and terms of the debt securities purchasable upon exercise of such debt warrants;

if applicable, the designation and terms of the securities with which such debt warrants are issued and the number of such debt warrants issued with each security;

if applicable, the date from and after which such debt warrants and any securities issued therewith will be separately transferable;

the principal amount of debt securities purchasable upon exercise of a debt warrant and the price at which such principal amount of debt securities may be purchased upon exercise;

the date on which the right to exercise such debt warrants shall commence and the date on which such right shall expire;

if applicable, the minimum or maximum amount of such debt warrants which may be exercised at any one time;

whether the debt warrants represented by the debt warrant certificates or debt securities that may be issued upon exercise of the debt warrants will be issued in registered form;

information with respect to book-entry procedures, if any;

the currency, currencies or currency units in which the offering price, if any, and the exercise price are payable;

if applicable, a discussion of certain United States federal income tax considerations;

the identity of the warrant agent for the warrants;

the antidilution provisions of such debt warrants, if any;

the redemption or call provisions, if any, applicable to such debt warrants; and

any additional terms of the debt warrants, including terms, procedures and limitations relating to the exchange and exercise of such debt warrants.

DESCRIPTION OF DEPOSITARY SHARES

The following briefly summarizes the provisions of the depositary shares and depositary receipts that we may issue from time to time and which would be important to holders of depositary shares and depositary receipts, other than pricing and related terms, which will be disclosed in the applicable prospectus supplement. The prospectus supplement will also state whether any of the general provisions summarized below do not apply to the depositary shares or depositary receipts being offered and provide any additional provisions applicable to the depositary shares or depositary receipts being offered. The following description and any description in a prospectus supplement may not be complete and are subject to, and qualified in their entirety by reference to the terms and provisions of the form of deposit agreement filed as an exhibit to the registration statement which contains this prospectus.

Depositary Shares

We may offer depositary shares evidenced by depositary receipts. Each depositary share represents a fraction or a multiple of a share of a particular series of preferred stock that we issue and deposit with a depositary. The fraction or the multiple of a share of preferred stock, which each depositary share represents, will be set forth in the applicable prospectus supplement.

We will deposit the shares of any series of preferred stock represented by depositary shares according to the provisions of a deposit agreement to be entered into between us and a bank or trust company, which we will select as its preferred stock depositary. We will name the depositary in the applicable prospectus supplement. Each holder of a depositary share will be entitled to all the rights and preferences of the underlying preferred stock in proportion to the applicable fraction or multiple of a share of preferred stock represented by the

Table of Contents

depository share. These rights include any applicable dividend, voting, redemption, conversion and liquidation rights. The depository will send the holders of depository shares all reports and communications that we deliver to the depository and which we are required to furnish to the holders of depository shares.

Depository Receipts

The depository shares will be evidenced by depository receipts issued pursuant to the deposit agreement. Depository receipts will be distributed to anyone who is buying the fractional shares of preferred stock in accordance with the terms of the applicable prospectus supplement.

Withdrawal of Preferred Stock

Unless the related depository shares have previously been called for redemption, a holder of depository shares may receive the number of whole shares of the related series of preferred stock and any money or other property represented by the holder's depository receipts after surrendering the depository receipts at the corporate trust office of the depository, paying any taxes, charges and fees provided for in the deposit agreement and complying with any other requirement of the deposit agreement. Partial shares of preferred stock will not be issued. If the surrendered depository shares exceed the number of depository shares that represent the number of whole shares of preferred stock the holder wishes to withdraw, then the depository will deliver to the holder at the same time a new depository receipt evidencing the excess number of depository shares. Once the holder has withdrawn the preferred stock, the holder will not be entitled to re-deposit that preferred stock under the deposit agreement or to receive depository shares in exchange for such preferred stock.

Dividends and Other Distributions

The depository will distribute to record holders of depository shares any cash dividends or other cash distributions it receives on preferred stock. Each holder will receive these distributions in proportion to the number of depository shares owned by the holder. The depository will distribute only whole U.S. dollars and cents. The depository will add any fractional cents not distributed to the next sum received for distribution to record holders of depository shares.

In the event of a non-cash distribution, the depository will distribute property to the record holders of depository shares, unless the depository determines that it is not feasible to make such a distribution. If this occurs, the depository may, with our approval, sell the property and distribute the net proceeds from the sale to the holders.

The amounts distributed to holders of depository shares will be reduced by any amounts required to be withheld by the preferred stock depository or by we on account of taxes or other governmental charges.

Redemption of Depository Shares

If the series of preferred stock represented by depository shares is subject to redemption, then we will give the necessary proceeds to the depository. The depository will then redeem the depository shares using the funds it received from us for the preferred stock. The redemption price per depository share will be equal to the redemption price payable per share for the applicable series of the preferred stock and any other amounts per share payable with respect to the preferred stock multiplied by the fraction of a share of preferred stock represented by one depository share. Whenever we redeem shares of preferred stock held by the depository, the depository will redeem the depository shares representing the shares of preferred stock on the same day, provided we have paid in full to the depository the redemption price of the preferred stock to be redeemed and any accrued and unpaid dividends. If fewer than all the depository shares of a series are to be redeemed, the depository shares will be selected by lot or ratably or by any other

equitable method as the depositary will decide.

After the date fixed for redemption, the depositary shares called for redemption will no longer be considered outstanding. Therefore, all rights of holders of the depositary shares will cease, except that the holders will still be entitled to receive any cash payable upon the redemption and any money or other property to which the holder

Table of Contents

was entitled at the time of redemption. To receive this amount or other property, the holders must surrender the depositary receipts evidencing their depositary shares to the preferred stock depositary. Any funds that we deposit with the preferred stock depositary for any depositary shares that the holders fail to redeem will be returned to us after a period of two years from the date we deposit the funds.

Voting the Preferred Stock

Upon receipt of notice of any meeting at which the holders of preferred stock are entitled to vote, the depositary will notify holders of depositary shares of the upcoming vote and arrange to deliver our voting materials to the holders. The record date for determining holders of depositary shares that are entitled to vote will be the same as the record date for the preferred stock. The materials the holders will receive will describe the matters to be voted on and explain how the holders, on a certain date, may instruct the depositary to vote the shares of preferred stock underlying the depositary shares. For instructions to be valid, the depositary must receive them on or before the date specified. To the extent possible, the depositary will vote the shares as instructed by the holder. We agree to take all reasonable actions that the depositary determines are necessary to enable it to vote as a holder has instructed. The depositary will abstain from voting shares of preferred stock deposited under a deposit agreement if it has not received specific instructions from the holder of the depositary shares representing those shares.

Amendment and Termination of the Deposit Agreement

We may agree with the depositary to amend the deposit agreement and the form of depositary receipt at any time. However, any amendment that materially and adversely alters the rights of the holders of depositary receipts will not be effective unless it has been approved by the holders of at least a majority of the affected depositary shares then outstanding. We will make no amendment that impairs the right of any holder of depositary shares, as described above under **Withdrawal of Preferred Stock**, to receive shares of preferred stock and any money or other property represented by those depositary shares, except in order to comply with mandatory provisions of applicable law. If an amendment becomes effective, holders are deemed to agree to the amendment and to be bound by the amended deposit agreement if they continue to hold their depositary receipts.

The deposit agreement automatically terminates if a final distribution in respect of the preferred stock has been made to the holders of depositary receipts in connection with our liquidation, dissolution or winding-up. We may also terminate the deposit agreement at any time we wish with at least 60 days prior written notice to the depositary. If we do so, the depositary will give notice of termination to the record holders not less than 30 days before the termination date. Once depositary receipts are surrendered to the depositary, it will send to each holder the number of whole or fractional shares of the series of preferred stock underlying that holder's depositary receipts.

Charges of Depositary and Expenses

We will pay all transfer and other taxes and governmental charges arising solely from the existence of the depositary arrangements. We will pay all charges of the depositary in connection with the initial deposit of the related series of offered preferred stock, the initial issuance of the depositary shares, all withdrawals of shares of the related series of offered preferred stock by holders of the depositary shares and the registration of transfers of title to any depositary shares. However, holders of depositary receipts will pay other taxes and governmental charges and any other charges provided in the deposit agreement to be payable by them.

Limitations on Our Obligations and Liability to Holders of Depositary Receipts

The deposit agreement will expressly limit our obligations and the obligations of the depositary. It will also limit our liability and the liability of the depositary as follows:

we and the depositary are only liable to the holders of depositary receipts for negligence or willful misconduct; and

we and the depositary have no obligation to become involved in any legal or other proceeding related to the depositary receipts or the deposit agreement on your behalf or on behalf of any other party, unless you provide us with satisfactory indemnity.

Table of Contents

Resignation and Removal of Depositary

The depositary may resign at any time by notifying us of its election to do so. In addition, we may remove the depositary at any time. Within 60 days after the delivery of the notice of resignation or removal of the depositary, we will appoint a successor depositary.

Reports to Holders

We will deliver all required reports and communications to holders of the offered preferred stock to the depositary, and it will forward those reports and communications to the holders of depositary shares.

ISSUANCE OF COMMON STOCK PURSUANT TO OUR ACQUISITION OF ESTECH

Effective December 31, 2013, we acquired Endoscopic Technologies, Inc., a Delaware corporation d/b/a Estech (Estech) pursuant to the terms of the Merger Agreement (the Merger Agreement), by and among AtriCure, Niners Merger Sub, LLC, a Delaware limited liability company and a subsidiary of AtriCure (Merger Sub), Estech and Fortis Advisors LLC, solely in its capacity as representative of the stockholders (Representative). As consideration for the merger, we paid upfront consideration of 1,957,816 shares of common stock and deposited an additional 168,527 shares of common stock into an escrow established pursuant to the Merger Agreement for post-closing claims.

Subject to meeting certain additional financial performance milestones throughout the two year period beginning January 1, 2014, as more particularly described in the Merger Agreement, the Estech stockholders will be eligible to receive an aggregate of up to an additional \$26,000,000 (the Earn-Out). The Earn-Out may be paid in a combination of cash and our common stock. This prospectus relates to the resale of the 2,126,343 shares of our common stock previously issued, and up to 500,000 additional shares that may be issued as Earn-Out, by us to the former stockholders of Estech (the Estech selling securityholders) in connection with the Merger Agreement.

SELLING SECURITYHOLDERS

Certain of the shares of common stock to be sold pursuant to this prospectus identified in the table below were issued in a private placement to Estech selling securityholders in connection with the consummation of transactions contemplated by the Merger Agreement described above in Issuance of Common Stock Pursuant to our Acquisition of Estech. The selling securityholder identified below as Camden Partners acquired its shares in private placements unrelated to the Merger Agreement. When we refer to the selling securityholders in this prospectus, we mean the entities listed in the table below, including both the Estech selling securityholders and Camden Partners, as well as their permitted transferees, assignees, donees, pledgees and successors in interest.

The Registration Statement of which this prospectus forms a part has been filed pursuant to registration rights granted to the Estech selling securityholders in the Merger Agreement in order to permit the Estech selling securityholders to resell to the public shares of our common stock, as well as any common stock that we may issue or may be issuable by reason of the Earn-Out. We will pay certain expenses of the registration of the selling securityholders' shares of our common stock, including SEC filing fees, but the selling securityholders will pay all underwriting discounts and commissions, if any.

The table below sets forth certain information known to us with respect to the beneficial ownership of the shares of our common stock held by the selling securityholders as of January 31, 2014. Given that the selling securityholders may sell, transfer or otherwise dispose of all, some or none of the shares of our common stock covered by this prospectus, we cannot determine the number of such shares that will be sold, transferred or otherwise disposed of by

the selling securityholders, or the amount or percentage of shares of our common stock that will be held by the selling securityholders upon termination of this offering. See Plan of Distribution. For the purposes of the table below, we assume that the selling securityholders will sell all of their shares of our common stock covered by this prospectus.

Table of Contents

In the table below, the percentage of shares beneficially owned is based on 23,363,948 shares of our common stock outstanding as of January 31, 2014. Beneficial ownership is determined under the rules of the SEC and generally includes voting or investment power with respect to securities. The entities named in the table below have sole voting and sole investment power with respect to all shares beneficially owned.

Except as described herein, none of the selling securityholders has had any material relationship with us except with respect to ownership of the shares of common stock.

Name and address of beneficial owner	Shares beneficially owned prior to this offering		Shares beneficially owned after offering		
	Common stock	Percentage of shares	Shares to be sold in offering	Common stock	Percentage of shares
Camden Partners (1) 500 East Pratt Street, Suite 1200 Baltimore, MD 21202	631,790	2.65%	631,790		
Saints Capital Everest L.P. (2)(3) 2020 Union Street San Francisco, CA 94123	1,470,367	6.16%	1,470,367		
NBGI Technology Fund II LP (2)(4) 128 Queen Victoria Street London, U.K EC4V 4BJ	287,486	1.20%	287,486		
Telegraph Hill Partners SBIC LP (2)(5) 360 Post Street, Suite 601 San Francisco, CA 94108	267,507	1.12%	267,507		
Tullis Opportunity Fund II, L.P. (2)(6) 55 Old Field Point Rd., 2 nd Floor Greenwich, CT 06830	129,383	*	129,383		
Waveland Ventures IV, LLC (2)(7) 19800 MacArthur Blvd., Suite 650 Irvine, CA 92612	103,265	*	103,265		
Waveland Ventures IV QP, LLC (2)(7) 19800 MacArthur Blvd., Suite 650 Irvine, CA 92612	96,732	*	96,732		
PED Estech, LLC (2)(8) Attn: E. Gray Lee 4525 Harding Pike, Suite 200 Nashville, TN 37205	82,655	*	82,655		
Waveland Ventures IV-A, LLC (2)(7) 19800 MacArthur Blvd., Suite 650 Irvine, CA 92612	34,502	*	34,502		
Waveland Ventures IV-B, LLC (2)(7) 19800 MacArthur Blvd., Suite 650 Irvine, CA 92612	25,016	*	25,016		
	53,122	*	53,122		

John Pavlidis(2) 573 Lassen Street Los Altos, CA 94022			
Terance Kinninger(2) P.O. Box 9112 Rancho Santa Fe, CA 92067	26,096	*	26,096
Tamer Ibrahim(2) 598 Bridgewater Circle Danville, CA 94526	26,096	*	26,096
Mark Koeniguer(2) 17417 Country Lake Estates Ridge Chesterfield, MO 63005	18,630	*	18,630
Randy Lindholm (2) 857 Indian River Drive Melbourne, FL 32935	5,486	*	5,486

Table of Contents

* denotes less than one percent

- (1) This selling securityholder's holdings consist of 585,405 shares held by Camden Partners Strategic Fund II-A, L.P., 34,727 shares held by Camden Partners Strategic Fund II-B, L.P. and 11,658 shares held by Camden Partners Holdings, LLC. Camden Partners Strategic II, LLC is the general partner of Camden Partners Strategic Fund II-A, L.P. and Camden Partners Strategic Fund II-B, L.P. David L. Warnock and Donald W. Hughes each may be deemed to share voting and investment power with respect to the securities held by these entities and disclaims beneficial ownership of the securities held by these entities, except as to his pecuniary interest therein. Richard M. Johnston, who has served as a director of AtriCure since June 2002 and as Chairman of the Board since February 2005, served as a Managing Member of both Camden Partners Holdings, LLC and Camden Partners Strategic II, LLC, and is now a Retired Member of each.
- (2) Includes shares of our common stock over which the selling securityholder has sole voting and dispositive power as well as shares of our common stock held in escrow over which Fortis Advisors LLC in its capacity as representative of the selling securityholder has sole voting power as follows: Saints Capital Everest L.P. 99,253 shares; NBGI Technology Fund II LP 19,401 shares; Telegraph Hill Partners SBIC LP 18,052 shares; Tullis Opportunity Fund II, L.P. 8,728 shares; Waveland Ventures IV, LLC 6,963 shares; Waveland Ventures IV QP, LLC 6531 shares; PED Estech, LLC 5,578 shares; Waveland Ventures IV-A, LLC 2,331 shares; and Waveland Ventures IV-B, LLC 1,690 shares. Also includes up to an aggregate of 500,000 shares of our common stock that may be issued as Earn-Out as follows: Saints Capital Everest L.P. 280,000 shares; NBGI Technology Fund II LP 54,800 shares; Telegraph Hill Partners SBIC LP 51,000 shares; Tullis Opportunity Fund II, L.P. 24,700 shares; Waveland Ventures IV, LLC 19,750 shares; Waveland Ventures IV QP, LLC 18,400 shares; PED Estech, LLC 15,750 shares; Waveland Ventures IV-A, LLC 6,550 shares; Waveland Ventures IV-B, LLC 4,750 shares; John Pavlidis 10,100 shares; Terance Kinninger 4,800 shares; Tamer Ibrahim 4,800 shares; Mark Koeniguer 3,550 shares; and Randy Lindholm 1,050 shares.
- (3) The general partner of Saints Capital Everest L.P. is Saints Capital Everest LLC, the managers of which are Scott Halsted, Kenneth Sawyer, David Quinlivana and Ghia Griate, each of whom may be deemed to share voting and investment power with respect to the securities and disclaims beneficial ownership of the securities, except to the extent of his/her pecuniary interest therein.
- (4) The general partner of NBGI Technology Fund II LP is NBG GP Limited and the manager of NBGI Technology Fund II LP is NBGI Private Equity Limited. NBG International Limited is the sole parent of both NBG GP Limited and NBGI Private Equity Limited and National Bank of Greece is the sole parent of NBG International Limited. Through board representation on these entities, Aris Constantindes may be deemed to share voting and investment power with respect to the securities and disclaims beneficial ownership of the securities, except to the extent of his/her pecuniary interest therein.
- (5) The general partner of Telegraph Hill Partners SBIC LP is Telegraph Hill Partners SBIC, LLC, the managers of which are Robert G. Shepler, J. Matthew Mackowski, Thomas A. Raffin, and Deval A. Lashkari, each of whom may be deemed to share voting and investment power with respect to the securities and disclaims beneficial ownership of the securities, except to the extent of his/her pecuniary interest therein.
- (6) The general partner of Tullis Opportunity Fund II, L.P. is Tullis Opportunity Fund II, LLC, the manager of which is James L.L. Tullis, who may be deemed to share voting and investment power with respect to the securities and disclaims beneficial ownership of the securities, except to the extent of his/her pecuniary interest therein.
- (7) The manager of each of Waveland Ventures IV, LLC, Waveland Ventures IV QP, LLC, Waveland Ventures IA-A, LLC and Waveland Ventures IV-B, LLC is Waveland Venture Partners LLC, the managers of which are Michael J. Greer and Vickie J. Greer, each of whom may be deemed to share voting and investment power with respect to the securities and disclaims beneficial ownership of the securities, except to the extent of his/her pecuniary interest therein.
- (8) The general partner of PED Estech, LLC is PED Investors, LLC, the manager of which is Thomas P. Ivanyi, who may be deemed to share voting and investment power with respect to the securities and disclaims beneficial ownership of the securities, except to the extent of his pecuniary interest therein.

Table of Contents

PLAN OF DISTRIBUTION

We and the selling securityholders may offer the securities covered by this prospectus in any of the following ways (or in any combination) from time to time:

to or through underwriters or dealers;

directly to purchasers or to a single purchaser; or

through agents; or

in at the market offerings, within the meaning of Rule 415(a)(4) of the Securities Act, to or through a market maker or into an existing trading market, on an exchange or otherwise.

In addition, we and any selling securityholder may enter into derivative or other hedging transactions with third parties, or sell securities not covered by this prospectus to third parties in privately negotiated transactions. If any applicable prospectus supplement indicates, in connection with such a transaction, such third parties may, pursuant to this prospectus and any applicable prospectus supplement, sell securities covered by this prospectus and any applicable prospectus supplement. If so, the third party may use securities borrowed from others to settle such sales and may use securities received from us to close out any related short positions. We and the selling securityholders may also loan or pledge securities covered by this prospectus and any applicable prospectus supplement to third parties, who may sell the loaned securities or, in an event of default in the case of a pledge, sell the pledged securities pursuant to this prospectus and any applicable prospectus supplement.

Any applicable prospectus supplement will set forth the terms of the offering of the securities covered by this prospectus, including:

the name or names of any underwriters, dealers or agents and the amounts of securities underwritten or purchased by each of them, if any;

any material relationship with the underwriter and the nature of such relationship, if any;

the over-allotment options under which underwriters may purchase additional securities, if any;

the public offering price or purchase price of the securities and the proceeds to us and any discounts, commissions, or concessions or other items constituting compensation allowed, re-allowed or paid to underwriters, dealers or agents, if any;

any securities exchanges on which the securities may be listed, if any; and

the manner for refunding any excess amount paid (including whether interest will be paid).

Any public offering price or purchase price and any discounts, commissions, concessions or other items constituting compensation allowed or re-allowed or paid to underwriters, dealers or agents may be changed from time to time.

The securities may be offered and sold from time to time in one or more transactions, including negotiated transactions, at a fixed price or prices or at varying prices determined at the time of sale. If underwriters are used in the sale of any securities, the securities will be acquired by the underwriters for their own account and may be resold from time to time in one or more transactions described above. The securities may be either offered to the public through underwriting syndicates represented by managing underwriters, or directly by underwriters. Generally, the underwriters' obligations to purchase the securities will be subject to certain conditions precedent. The underwriters will be obligated to purchase all of the securities if they purchase any of the securities.

We and the selling securityholders may sell the securities through agents from time to time. If required by applicable law, any applicable prospectus supplement will name any agent involved in the offer or sale of the securities and any commissions we pay to them. Generally, unless otherwise indicated in any applicable

Table of Contents

prospectus supplement, any agent will be acting on a best efforts basis for the period of its appointment. If a dealer is used in the sale of the securities in respect of which the prospectus is delivered, we or the selling stockholders will sell such securities to the dealer, as principal. The dealer may then resell such securities to the public at varying prices to be determined by such dealer at the time of resale.

We and the selling securityholders may authorize underwriters, dealers or agents to solicit offers by certain purchasers to purchase the securities from us at the public offering price set forth in any applicable prospectus supplement or other prices pursuant to delayed delivery or other contracts providing for payment and delivery on a specified date in the future. Any delayed delivery contracts will be subject only to those conditions set forth in any applicable prospectus supplement, and any applicable prospectus supplement will set forth any commissions we pay for solicitation of these delayed delivery contracts.

Each underwriter, dealer and agent participating in the distribution of any offered securities that are issuable in bearer form will agree that it will not offer, sell, resell or deliver, directly or indirectly, offered securities in bearer form in the United States or to United States persons except as otherwise permitted by Treasury Regulations Section 1.163-5(c)(2)(i)(D).

Offered securities may also be offered and sold, if so indicated in any applicable prospectus supplement, in connection with a remarketing upon their purchase, in accordance with a redemption or repayment pursuant to their terms, or otherwise, by one or more remarketing firms, acting as principals for their own accounts or as agents for us or the selling securityholders. Any remarketing firm will be identified and the terms of its agreements, if any, with us, and its compensation will be described in any applicable prospectus supplement.

We and the selling securityholders may sell equity securities in an offering at the market, as defined in Rule 415 under the Securities Act. A post-effective amendment to this Registration Statement will be filed to identify the underwriter(s) at the time of the take-down for at the market offerings.

Agents, underwriters and other third parties described above may be entitled under relevant underwriting or other agreements to indemnification by us or the selling securityholders against certain civil liabilities under the Securities Act, or to contribution with respect to payments which the agents, underwriters or other third parties may be required to make in respect thereof. Agents, underwriters and such other third parties may be customers of, engage in transactions with, or perform services for us or the selling Securityholders in the ordinary course of business.

LEGAL MATTERS

The validity of the securities offered by this prospectus will be passed upon for us by Keating Muething & Klekamp PLL, Cincinnati, Ohio.

EXPERTS

The consolidated financial statements and the related financial statement schedule, incorporated in this prospectus by reference from the Company's Annual Report on Form 10-K and the effectiveness of AtriCure's internal control over financial reporting have been audited by Deloitte & Touche LLP, an independent registered public accounting firm, as stated in their reports, which are incorporated by reference herein. Such financial statements and financial statement schedule have been so incorporated in reliance upon the reports of such firm given upon their authority as experts in accounting and auditing.

The financial statements of Endoscopic Technologies, Inc. as of and for the year ended December 31, 2012, included in this prospectus, have been audited by Moss Adams LLP, independent auditors, as stated in their report. Such financial statements have been included in reliance upon the reports of such firm given upon their authority as experts in accounting and auditing.

Table of Contents

The financial statements of Endoscopic Technologies, Inc. as of and for the year ended December 31, 2011, included in this prospectus, have been audited by Mohler, Nixon & Williams, independent auditors, as stated in their report. Such financial statements have been included in reliance upon the reports of such firm given upon their authority as experts in accounting and auditing.

Table of Contents

FINANCIAL STATEMENTS
INDEX TO FINANCIAL STATEMENTS
OF
ENDOSCOPIC TECHNOLOGIES, INC.

<u>Reports of Independent Auditors</u>	F-2
<u>Balance Sheets as of September 30, 2013 (unaudited), December 31, 2012 and December 31, 2013</u>	F-5
<u>Statements of Operations for the Nine Months Ended September 30, 2013 (unaudited) and September 30, 2012 (unaudited) and for the Years Ended December 31, 2012 and December 31, 2011</u>	F-6
<u>Statements of Stockholders' Equity for the Nine Months Ended September 30, 2013 (unaudited) and for the Years Ended December 31, 2012 and December 31, 2011</u>	F-7
<u>Statements of Cash Flows for the Nine Months Ended September 30, 2013 (unaudited) and September 30, 2012 (unaudited) and for the Years Ended December 31, 2012 and December 31, 2011</u>	F-10
<u>Notes to Financial Statements</u>	F-11

INDEX TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION
OF
ATRICURE, INC. AND SUBSIDIARIES AND ENDOSCOPIC TECHNOLOGIES, INC.

<u>Unaudited Pro Forma Condensed Combined Financial Information</u>	F-25
<u>Condensed Combined Balance Sheet and Pro Form Adjustments as of September 30, 2013 (unaudited)</u>	F-26
<u>Condensed Combined Statement of Continuing Operations and Pro Forma Adjustments for the Nine Months Ended September 30, 2013 (unaudited)</u>	F-27
<u>Condensed Combined Statement of Continuing Operations and Pro Forma Adjustments for the Year Ended December 31, 2012</u>	F-28
<u>Notes to Unaudited Pro Forma Condensed Combined Financial Information</u>	F-29

F-1

Table of Contents

REPORT OF INDEPENDENT AUDITORS

To the Board of Directors

and Stockholders of

Endoscopic Technologies, Inc.

Report on Financial Statements

We have audited the accompanying financial statements of Endoscopic Technologies, Inc. (the Company), which comprise the balance sheet as of December 31, 2012, and the related statements of operations, stockholders' equity, and cash flows for the year then ended, and the related notes to the financial statements.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence obtained is sufficient and appropriate to provide a basis for our audit opinion.

Table of Contents

Opinion

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2012, and the results of its operations and its cash flows for the year then ended, in accordance with accounting principles generally accepted in the United States of America.

Other Matter

The financial statements of the Company as of and for the year ended December 31, 2011 were audited by other auditors whose report, dated May 21, 2012, expressed an unmodified opinion on those statements.

Campbell, California

April 19, 2013

F-3

Table of Contents

REPORT OF INDEPENDENT AUDITORS

To the Board of Directors

and Stockholders of

Endoscopic Technologies, Inc.

We have audited the accompanying balance sheet of Endoscopic Technologies, Inc. (the Company) as of December 31, 2011, and the related statements of operations, stockholders' equity, and cash flows for the year then ended. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audit.

We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2011, and the results of its operations and cash flows for the year then ended, in conformity with accounting principles generally accepted in the United States of America.

MOHLER, NIXON & WILLIAMS

Accountancy Corporation

Campbell, California

May 21, 2012

635 Campbell Technology Parkway Campbell, California 95008-5071 Tel 408-369-2400 Fax 408-879-9455

2600 El Camino Real, Suite 405 Palo Alto, California 94306-1719 Tel 650-494-3901 Fax 650-494-6756

150 Spear Street, Suite 925 San Francisco, California 94105-1535 Tel 415-817-5070 Fax 415-896-1721

www.mohlernixon.com

F-4

Table of Contents**ENDOSCOPIC TECHNOLOGIES, INC.****BALANCE SHEETS**

	September 30, 2013 (unaudited)	December 31, 2012	December 31, 2011
Assets			
Cash and cash equivalents	\$ 3,092,596	\$ 996,587	\$ 6,774,865
Restricted cash		1,000,000	1,000,000
Accounts receivable, net	2,825,481	3,245,594	3,249,610
Inventories	3,161,816	3,773,637	2,507,790
Prepaid expenses and other current assets	648,304	308,281	578,988
Total current assets	9,728,197	9,324,099	14,111,253
Property and equipment, net	1,452,075	1,497,571	1,153,098
Intangible assets, net	10,868,286	11,590,512	12,484,689
Other assets	50,569	164,199	182,624
Total assets	\$ 22,099,127	\$ 22,576,381	\$ 27,931,664
Liabilities and stockholders' equity			
Accounts payable	\$ 1,609,475	\$ 1,503,563	\$ 2,157,655
Accrued liabilities	1,663,615	2,299,244	2,943,528
Borrowings under line of credit		1,500,000	2,166,194
Current portion of notes payable, net	1,818,182	1,676,211	
Total current liabilities	5,091,272	6,979,018	7,267,377
Long-term accrued liabilities		150,000	700,000
Warrant liability, at fair value (Note 6)	93,802		
Notes payable, less current portion	8,181,818	2,687,154	8,193,337
Total liabilities	13,366,892	9,816,172	16,160,714
Commitments and contingencies (Note 12)			
Stockholders' equity			
Series D-1 convertible preferred stock, \$0.001 par value; 21,921,253 shares authorized: 21,921,253, 21,921,253, and 7,754,314 shares issued and outstanding at September 30, 2013 (unaudited) and December 31, 2012 and 2011, respectively (aggregate liquidation preference of \$16,660,152 and \$5,893,278 at December 31, 2012 and 2011, respectively)	12,011,803	12,011,803	5,402,721
Series C-1 convertible preferred stock, \$0.001 par value; 12,481,834 shares authorized, issued, and outstanding at	8,353,978	8,353,978	8,353,978

September 30, 2013 (unaudited) and December 31, 2012 and 2011 (aggregate liquidation preference of \$8,762,247)			
Series B-1 convertible preferred stock, \$0.001 par value; 12,871,729 shares authorized: 12,841,729 shares issued and outstanding at September 30, 2013 (unaudited) and December 31, 2012 and 2011 (aggregate liquidation preference of \$11,237,155)	10,346,888	10,346,888	10,346,888
Series A-1 convertible preferred stock, \$0.001 par value; 17,874,137 shares authorized, issued, and outstanding at September 30, 2013 (unaudited), December 31, 2012 and 2011 (aggregate liquidation preference of \$23,851,070)	39,954,470	39,954,470	39,954,470
Common stock, \$0.001 par value; 100,000,000 shares authorized: 3,660,235, 7,593,059, and 7,562,309 shares issued and outstanding at September 30, 2013 (unaudited) and December 31, 2012 and 2011, respectively	3,967	7,900	7,870
Additional paid-in capital	17,338,586	17,833,855	14,642,649
Notes receivables from stockholders	(152,422)	(943,987)	(935,908)
Accumulated deficit	(79,125,035)	(74,804,698)	(66,001,718)
Total stockholders equity	8,732,235	12,760,209	11,770,950
Total liabilities and stockholders equity	\$ 22,099,127	\$ 22,576,381	\$ 27,931,664

See accompanying notes.

Table of Contents**ENDOSCOPIC TECHNOLOGIES, INC.****STATEMENTS OF OPERATIONS**

	Nine months ended September 30,		Years ended December 31,	
	2013	2012	2012	2011
	(unaudited)	(unaudited)		
Revenue	\$ 14,913,551	\$ 14,665,446	\$ 19,629,460	\$ 21,854,184
Cost of revenue	4,038,159	4,061,859	5,509,416	5,947,628
Gross profit	10,875,392	10,603,587	14,120,044	15,906,556
Operating expenses:				
Research and development	2,395,420	2,393,483	3,136,677	3,060,308
Sales and marketing	7,027,332	7,972,994	10,577,945	13,364,199
General and administrative	2,892,903	2,860,690	3,746,779	3,252,991
Depreciation and amortization	1,079,100	1,086,192	1,445,707	1,679,179
Stock-based compensation	291,113	184,526	246,034	292,921
Total operating expenses	13,685,868	14,497,885	19,153,142	21,649,598
Loss from operations	(2,810,476)	(3,894,298)	(5,033,098)	(5,743,042)
Gain on sale of product line				3,401,491
Interest income	94,368	141,488	224,578	202,148
Interest and other expense, net	(1,591,722)	(836,283)	(1,002,218)	(888,216)
Beneficial conversion feature and cost of warrants	(12,507)	(2,978,944)	(2,992,242)	(183,333)
Net loss	\$ (4,320,337)	\$ (7,568,037)	\$ (8,802,980)	\$ (3,210,952)

See accompanying notes.

Table of Contents

ENDOSCOPIC TECHNOLOGIES, INC.

STATEMENTS OF STOCKHOLDERS EQUITY

	Series C-1 convertible preferred stock		Series B-1 convertible preferred stock		Series A-1 convertible preferred stock		Common stock		Additional paid-in capital	Net receivable from stock
	Shares	Amount	Shares	Amount	Shares	Amount	Shares	Amount		
1	12,481,834	\$ 8,364,856	12,841,729	\$ 10,346,888	17,874,137	\$ 39,954,470	7,847,115	\$ 7,848	\$ 15,687,704	\$ (2,000,000)
2										
3		(10,878)								
									189,824	
									183,333	
							(308,299)		(1,519,073)	1,000,000
									(196,737)	
							23,493	22	4,677	
									284,581	

See accompanying notes.

F-7

Table of Contents

Account	Series C-1 convertible preferred stock		Series B-1 convertible preferred stock		Series A-1 convertible preferred stock		Common stock		Additional paid-in capital	Net receivable stock
	Shares	Amount	Shares	Amount	Shares	Amount	Shares	Amount		
									8,340	
2,721	12,481,834	8,353,978	12,841,729	10,346,888	17,874,137	39,954,470	7,562,309	7,870	14,642,649	(9)
									2,939,052	
							30,750	30	6,120	
									244,701	
									1,333	

See accompanying notes.

F-8

Table of Contents

Series C-1 convertible preferred stock		Series B-1 convertible preferred stock		Series A-1 convertible preferred stock		Common stock		Additional paid-in capital	retained earnings
Shares	Amount	Shares	Amount	Shares	Amount	Shares	Amount		
12,481,834	8,353,978	12,841,729	10,346,888	17,874,137	39,954,470	7,593,059	7,900	17,833,855	(1,000,000)
						(3,957,824)	(3,958)	(787,607)	
						25,000	25	1,225	
								291,113	
12,481,834	\$ 8,353,978	12,841,729	\$ 10,346,888	17,874,137	\$ 39,954,470	3,660,235	\$ 3,967	\$ 17,338,586	\$ (1,000,000)

See accompanying notes.

Table of Contents**ENDOSCOPIC TECHNOLOGIES, INC.****STATEMENTS OF CASH FLOWS**

	Nine months ended		Years ended	
	September 30,	September 30,	December 31,	December 31,
	2013	2012	2012	2011
	(unaudited)	(unaudited)		
Cash flows from operating activities:				
Net loss	\$ (4,320,337)	\$ (7,568,037)	\$ (8,802,980)	\$ (3,210,952)
Adjustments to reconcile net loss to net cash used by operating activities:				
Loss on disposal of property and equipment	23,390	46,129	57,001	162,858
Depreciation	601,221	605,487	828,111	716,056
Amortization of intangible assets	722,226	722,360	964,177	963,123
Stock-based compensation	291,113	184,526	246,034	292,921
Non-cash interest expense	149,141	3,230,749	3,235,967	514,771
Gain on sale of product line				(3,401,491)
Changes in assets and liabilities:				
Restricted cash	1,000,000			(1,000,000)
Accounts receivable	420,113	573,115	4,016	(36,184)
Inventory	611,821	(1,252,591)	(1,265,847)	(223,487)
Prepaid expenses and other current assets	(258,728)	12,918	270,707	(294,837)
Other assets	113,630	7,062	18,425	(112,245)
Accounts payable	105,912	6,498	(654,092)	149,477
Accrued liabilities	(785,629)	(1,323,843)	(1,194,284)	492,916
Net cash used by operating activities	(1,326,127)	(4,755,627)	(6,292,765)	(4,987,074)
Cash flows from investing activities:				
Net cash proceeds on sale of product line				3,868,712
Purchase of property and equipment, and transfers from inventory	(579,115)	(945,898)	(1,229,585)	(680,115)
Acquisition of intangible asset		(70,000)	(70,000)	
Net cash provided (used) by investing activities	(579,115)	(1,015,898)	(1,299,585)	3,188,597
Cash flows from financing activities:				
Proceeds from sale of common stock	1,250	6,150	6,150	4,699
Proceeds from sale of preferred stock, net		1,928,884	2,474,116	500,002
Proceeds from issuance of convertible promissory notes, net				500,000
Proceeds from borrowings	10,000,000		2,000,000	6,666,194
Repayments of borrowing	(5,999,999)	(1,166,194)	(2,666,194)	(2,853,581)
Net cash provided by financing activities	4,001,251	768,840	1,814,072	4,817,314

Net increase (decrease) in cash and cash equivalents	2,096,009	(5,002,685)	(5,778,278)	3,018,837
Cash and cash equivalents at beginning of year	996,587	6,774,865	6,774,865	3,756,028
Cash and cash equivalents at end of year	\$ 3,092,596	\$ 1,772,180	\$ 996,587	\$ 6,774,865
Supplemental disclosure of cash flow information:				
Cash paid for interest	\$ 631,443	\$ 415,355	\$ 538,250	\$ 366,897
Non-cash investing and financing items:				
Issuance of common stock warrants	\$	\$	\$	\$ 2,668
Issuance of Series D-1 convertible preferred stock warrants	\$ 93,802	\$	\$	\$ 187,156
Beneficial conversion feature on promissory notes	\$	\$ 2,939,052	\$ 2,939,052	\$ 183,333
Conversion of convertible promissory notes payable and accrued interest into convertible preferred stock	\$	\$ 4,134,966	\$ 4,134,966	\$
Repurchase of common stock through cancellation of stockholder notes	\$ 791,565	\$	\$	\$

See accompanying notes.

Table of Contents**NOTE 1 THE COMPANY AND ITS SIGNIFICANT ACCOUNTING POLICIES**

Endoscopic Technologies, Inc. (the Company), doing business as ESTECH, was incorporated in California in April 1996 and reincorporated in Delaware in October 2009. The Company develops, manufactures, and markets a variety of medical devices to assist surgeons in performing minimally invasive cardiac surgery.

Liquidity Through December 31, 2012, the Company has incurred operating losses resulting in an accumulated deficit of approximately \$75,000,000. Additional funds are necessary to maintain current operations and to continue development activities. The Company intends to raise additional funds through the sale of its equity securities and/or debt financings. However, there can be no assurance that sufficient funding will be available to allow the Company to successfully complete and achieve widespread market acceptance of its products. If the Company is unable to obtain necessary funds, significant reductions in spending and the delay or cancellation of planned activities may be necessary. These actions would have a material adverse effect on the Company's business, results of operations and prospects.

Unaudited interim financial information The accompanying interim balance sheet as of September 30, 2013, the statements of operations and cash flows for the nine months ended September 30, 2013 and 2012, and the statement of stockholders' equity for the nine months ended September 30, 2013 are unaudited. These unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. In the opinion of the Company's management, the unaudited interim financial statements have been prepared on the same basis as the audited financial statements and include all adjustments, which include only normal recurring adjustments necessary for the fair presentation of the Company's statement of financial position as of September 30, 2013, and its results of operations and its cash flows for the nine months ended September 30, 2013 and 2012. The financial data and other financial information disclosed in these notes to financial statements related to September 30, 2013 and for the nine months ended September 30, 2013 and 2012 are also unaudited. The results for the nine months ended September 30, 2013 are not necessarily indicative of the results expected for the full fiscal year.

Estimates The preparation of the financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Cash equivalents The Company considers all highly liquid investments with an original maturity from the date of purchase of three months or less to be cash equivalents. As of September 30, 2013 (unaudited) December 31, 2012 and 2011, cash and cash equivalents consist of cash deposited with banks and money market funds. The recorded carrying amount of cash equivalents, which is cost plus accrued interest, approximates fair value. The Company places its cash equivalents with high credit-quality financial institutions.

Restricted cash Restricted cash of zero as of September 30, 2013 (unaudited) and \$1,000,000 as of December 31, 2012 and 2011 relates to a cash balance required by the Company's growth capital line of credit (Note 4).

Concentrations of credit risk Financial instruments that potentially subject the Company to credit risk consist primarily of cash and cash equivalents and accounts receivable. Cash and cash equivalents are deposited with federally insured commercial banks in the United States and at times cash balances may be in excess of federal insurance limits. Accounts receivable are stated at the amount the Company expects to collect. The Company generally does not require collateral or other security in support of accounts receivable. The Company performs ongoing credit evaluations of its customers' financial condition and maintains an allowance for doubtful accounts to ensure trade receivables are not overstated due to uncollectibility. The allowance for doubtful accounts is determined

based on a variety of factors, including the length of time receivables are past due, macroeconomic conditions, significant one-time events, and historical experiences. Allowances are recorded for individual accounts when the Company becomes aware of a customer's inability to meet its financial obligations, such as in

F-11

Table of Contents

the case of bankruptcy, deterioration in the customer's operating results, or change in financial position. Based on management's assessment, the Company provides for estimated uncollectible amounts through a charge to earnings and a credit to a valuation allowance. Balances that remain outstanding after the Company has used reasonable collection efforts are written off through a charge to the valuation allowance and a credit to accounts receivable. As of September 30, 2013 (unaudited) and December 31, 2012 and 2011, the Company's allowance for doubtful accounts receivable, including sales return reserves, was approximately \$ 109,000, \$150,000, and \$379,000, respectively.

The Company's revenues are derived from customers located in and outside the United States of America. One customer accounted for 10% (unaudited) of total accounts receivable as of September 30, 2013, and approximately 21% (unaudited) of total revenues for the nine months ended September 30, 2013. One customer accounted for approximately 19% (unaudited) of total revenues for the nine months ended September 30, 2012. One customer accounted for approximately 11% of total accounts receivables at December 31, 2012 and approximately 17% of total revenue in 2012. One customer accounted for approximately 10% of total accounts receivable at December 31, 2011 and no individual customer accounted for more than 10% of total revenue in 2011.

Net purchases include purchases from two vendors of approximately 41% in 2012. Accounts payable to these vendors totaled approximately 44% at December 31, 2012. Net purchases include purchases from two vendors of approximately 46% and 35% for the nine months ended September 30, 2013 and 2012, respectively (unaudited). Accounts payable to these vendors totaled approximately 31% at September 30, 2013 (unaudited).

Inventories Inventories are valued at standard cost, which approximates actual cost computed on a first-in, first-out basis, not in excess of market value. The Company periodically reviews its inventories for potential slow-moving or obsolete items and writes down specific items to net realizable value as appropriate. Inventory consists primarily of finished goods and purchased parts and unsterilized finished goods.

Property and equipment Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets, generally 27 to 120 months. Leasehold improvements are amortized using the term of the related lease or the economic life of improvements, if shorter. Upon disposition, the cost and related accumulated depreciation are removed from the accounts and the resulting gain or loss is reflected in the statements of operations.

Intangible assets Intangible assets comprise internally generated patents and licensing agreements, which are stated at cost less accumulated amortization. In addition, intangible assets include technology and distribution rights acquired from Boston Scientific Corporation (BSC) for the Company's COBRA product line (Note 11). Amortization is computed using the straight-line method over the estimated useful life of the respective patents or licensing agreements, generally 17 to 20 years. The Company evaluates the recoverability of identifiable intangible assets whenever events or changes in circumstances indicate that an intangible asset's carrying amount may not be recoverable. No impairment losses have been recorded to date.

Long-lived assets The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. No such impairments have been identified to date.

Research and development Research and development costs are charged to operations as incurred.

Revenue recognition The Company accounts for revenue in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 605, *Revenue Recognition*. The Company determines the timing of revenue recognition based upon factors such as passage of title, payment terms and ability to return products. The

Company recognizes revenue when all of the following criteria are met: (i) there is persuasive evidence that an arrangement exists; (ii) delivery of the products and/or services has occurred; (iii) the selling price is fixed or determinable; and (iv) collectability is reasonably assured.

F-12

Table of Contents

Product revenues are generated primarily from sales of the Company's medical tools. Pursuant to the Company's standard terms of sale, the Company recognizes revenue at the point of shipment to its customers, under the contractual terms, provided that no significant vendor obligation exists and collections of accounts receivable are reasonable assured. The Company generally does not maintain any post-shipping obligations to the recipients of the products. No installation, calibration or testing of this equipment is performed by the Company subsequent to shipment to the customer in order to render it operational.

Stock-based compensation The Company uses the estimated grant date calculated value method of accounting for stock-based compensation. The Company recognizes these compensation costs on a straight-line basis over the requisite service period of the award, which is generally the option vesting term of four years.

Income taxes Deferred tax liabilities and assets are recognized for the expected future tax consequences of temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities and net operating loss (NOL) and tax credit carryforwards. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.

The Company accounts for uncertainty in income taxes using a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. The Company classifies any liabilities for unrecognized tax benefits as current to the extent that the Company anticipates payment (or receipt) of cash within one year. Interest and penalties related to uncertain tax positions are recognized in the provision for income taxes. The Company had no liabilities for unrecognized tax benefits at September 30, 2013 (unaudited) and December 31, 2012 and 2011.

Reclassifications Certain reclassifications were made to the 2011 financial statements to conform them to the 2012 financial statement presentation.

Subsequent events The Company has evaluated subsequent events through January 7, 2014, which is the date the financial statements were available to be issued. Subsequent events after April 19, 2013 are unaudited.

NOTE 2 FAIR VALUE MEASUREMENT

The fair value measurements standard establishes a framework for measuring fair value. That framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements). The three levels of the fair value hierarchy under the standard are described below:

Level 1 Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the Company has the ability to access.

Level 2 Inputs to the valuation methodology include:

Quoted market prices for similar assets or liabilities in active markets;

Quoted prices for identical or similar assets or liabilities in inactive markets;

Inputs other than quoted prices that are observable for the asset or liability;

Inputs that are derived principally from or corroborated by observable market data by correlation or other means.

If the asset or liability has a specified (contractual) term, the level 2 input must be observable for substantially the full term of the asset or liability.

Level 3 Inputs to the valuation methodology are unobservable and significant to the fair value measurement.

Table of Contents

The asset's or liability's fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs.

Following is a description of the valuation methodology used for assets measured at fair value. There have been no changes in the methodology used at September 30, 2013 (unaudited) and December 31, 2012 and 2011.

The Company's money market funds of approximately \$2,255,000, \$305,000, and \$3,005,000 at September 30, 2013 (unaudited) and December 31, 2012 and 2011, respectively, are valued at the net asset value of shares held by the Company at year end and are considered level 1 within the fair value hierarchy. The money market funds are included in cash and cash equivalents as of September 30, 2013 (unaudited) and December 31, 2012 and 2011.

The method described above may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while the Company believes its valuation method is appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

NOTE 3 SIGNIFICANT BALANCE SHEET COMPONENTS

Inventories Inventories consisted of approximately the following at:

	September 30, 2013 (unaudited)	December 31, 2012	2011
Purchased parts and unsterilized finished goods	\$ 1,135,000	\$ 1,775,000	\$ 1,015,000
Finished goods	2,027,000	1,999,000	1,493,000
	\$ 3,162,000	\$ 3,774,000	\$ 2,508,000

At September 30, 2013 (unaudited) and December 31, 2012 and 2011, the reserve for obsolescence was \$352,000, \$309,000, and \$497,000, respectively.

Property and equipment Property and equipment consisted of approximately the following at:

	September 30, 2013 (unaudited)	December 31, 2012	2011
Equipment	\$ 2,178,000	\$ 1,961,000	\$ 1,438,000
Demonstration equipment	2,179,000	1,991,000	1,608,000
Computer equipment and software	665,000	618,000	528,000
Furniture and fixtures	201,000	200,000	196,000
	5,223,000	4,770,000	3,770,000

Edgar Filing: AtriCure, Inc. - Form 424B5

Less: accumulated depreciation	(3,771,000)	(3,272,000)	(2,617,000)
	\$ 1,452,000	\$ 1,498,000	\$ 1,153,000

Depreciation expense for the years ended December 31, 2012 and 2011 was approximately \$828,000 and \$716,000, respectively. Depreciation expense for the nine months ended September 30, 2013 and 2012 was approximately \$601,000 and \$605,000, respectively (unaudited).

F-14

Table of Contents

Intangible assets The components of intangible assets were approximately as follows as of:

	September 30, 2013 (unaudited)	December 31, 2012	December 31, 2011
COBRA product line	\$ 15,420,000	\$ 15,420,000	\$ 15,420,000
Medtronic license	1,800,000	1,800,000	1,800,000
Patents and other intangible assets	1,822,000	1,822,000	1,752,000
	19,042,000	19,042,000	18,972,000
Less: accumulated amortization	(8,174,000)	(7,451,000)	(6,487,000)
	\$ 10,868,000	\$ 11,591,000	\$ 12,485,000

Amortization expense for the years ended December 31, 2012 and 2011 was approximately \$964,000 and \$963,000, respectively. Amortization expense for the nine months ended September 30, 2013 and 2012, respectively was approximately \$722,000 (unaudited). (See Note 11 for COBRA product line and Medtronic license). Future amortization is expected to be approximately as follows:

Years ending December 31:	
2013	\$ 964,000
2014	944,000
2015	944,000
2016	944,000
2017	944,000
Thereafter	6,851,000
	\$ 11,591,000

As of September 30, 2013 (unaudited), the future amortization for the three months remaining in the year ending December 31, 2013 is approximately \$241,000. The amortization remains the same for the remaining years listed in the schedule above.

Accrued liabilities Accrued liabilities consisted of approximately the following at:

	September 30, 2013 (unaudited)	December 31, 2012	December 31, 2011
Employee-related liabilities	\$ 556,000	\$ 399,000	\$ 423,000
Professional and other fees	94,000	187,000	481,000
Commission and bonus	368,000	463,000	1,206,000
Deferred rent			6,000

Edgar Filing: AtriCure, Inc. - Form 424B5

Other accrued liabilities		646,000	1,250,000	828,000
Total accrued liabilities	current	\$ 1,664,000	\$ 2,299,000	\$ 2,944,000
Other liabilities	noncurrent	\$	\$ 150,000	\$ 700,000

In 2009, the Company agreed to settle a dispute with a government agency regarding allegations that the Company marketed one of its products in a manner without appropriate government agency approval. The Company agreed to such settlement without admitting to such allegations. Under the settlement, the Company paid approximately \$337,000 in 2012, and will pay approximately \$550,000 in 2013 and \$150,000 in 2014. As of December 31, 2012, approximately \$550,000 and \$150,000 have been recorded as a current liability and noncurrent liability, respectively.

F-15

Table of Contents**NOTE 4 FINANCING ARRANGEMENTS**

In December 2011, the Company amended its growth capital line with a financial institution that provides for a \$3,000,000 revolving line of credit to finance accounts receivable and inventory, and a \$1,000,000 term loan to finance working capital requirements. The agreement requires that the Company comply with certain loan covenants as defined.

Line of credit The line of credit agreement provides for borrowings of: (a) 80% of eligible accounts receivable, plus (b) the lesser of (i) 70% of the Borrower's Eligible Foreign Accounts or (ii) One Million Two Hundred Fifty Thousand Dollars (\$1,250,000), plus (c) the lesser of (i) 25% of the value of Borrower's Eligible Inventory (valued at the lower of cost or wholesale fair market value) or (ii) Five Hundred Thousand Dollars (\$500,000), each as determined by Bank from Borrower's most recent Transaction Report.

The amended revolving line of credit was repaid in January 2012 and an additional \$2,000,000 was drawn against the amended revolving line of credit during 2012. The revolving line of credit expires in December 2014, and borrowings under the line of credit accrue interest at 2.75% above the prime rate. As of September 30, 2013 and December 31, 2012 and 2011, aggregate borrowings under the growth capital line were zero (unaudited), approximately \$1,500,000 and \$2,166,000, respectively.

On March 21, 2013, the Company entered into a secured promissory note for \$10,000,000. The note matures on December 21, 2016, and borrowings under the note accrue interest at 10% per annum. The note was used to repay in full the outstanding borrowings under the Company's growth capital line and term loans (Note 4) of approximately \$6,127,000. In connection with the new note, the Company issued a warrant to purchase 394,737 shares of Series D-1 convertible preferred stock (Series D-1) for \$0.76 per share. The borrowings are secured by substantially all the Company's assets.

Long-term debt Along with the revolving line of credit, the Company entered into an agreement with the same financial institution for a \$1,000,000 term loan and a separate agreement with another financial institution for a \$3,500,000 term loan. Principal payments under both term loans are repayable in 30 monthly installments beginning in January 2013; however, there are minimum interest payments beginning in January 2012. Borrowings under the \$1,000,000 term loan accrue interest at 4.5% per annum paid monthly, with a final payment upon expiration of the loan in June 2015 of 5.5%. Borrowings under the \$3,500,000 term loan accrue interest at 10.5% per annum paid monthly, with a final payment upon expiration of the loan in June 2015 of 4.5%. As of September 30, 2013 (unaudited) and December 31, 2012 and 2011, aggregate borrowings under the term loans and the secured promissory note were approximately \$10,000,000 (unaudited) \$4,500,000, and \$4,500,000, respectively.

In December 2011, in connection with its amended growth capital line and term loans, the Company issued warrants to purchase 50,000 shares of its common stock and 458,224 shares of its Series D-1 (Note 6) which are valued at \$3,000 and \$187,000, respectively, to be amortized over the term of the debts.

Future minimum payments under the growth capital line and term loans as of December 31, 2012 are approximately as follows:

Years ending December 31:	
2013	\$ 1,676,000
2014	1,839,000

Edgar Filing: AtriCure, Inc. - Form 424B5

2015	985,000
	4,500,000
Less: debt discount	(137,000)
	4,363,000
Less: current portion	1,676,000
Long-term portion	\$ 2,687,000

F-16

Table of Contents

Future minimum payments under the secured promissory note as of September 30, 2013 (unaudited) are approximately as follows:

Years ending December 31:	
2013	\$
2014	2,728,000
2015	3,636,000
2016	3,636,000
	10,000,000
Less: current portion	1,818,000
Long-term portion	\$ 8,182,000

Convertible notes payable In November and December 2010 and January 2011, the Company issued convertible notes payable aggregating \$3,500,000 with an interest rate of 10% per annum. In September 2012, approximately \$4,135,000 of these notes and accrued interest thereon was converted to shares of Series D-1 at 50% of the fair value. The amounts outstanding on these notes as of December 31, 2012 and 2011, including interest, are zero and approximately \$3,883,000, respectively.

The convertible promissory notes issued in 2010 and 2011 had conversion rates that provided for a discount from the fair value of Series D-1. As a result, during the years ended December 31, 2012 and 2011, the Company recognized a beneficial conversion feature of approximately \$2,939,000 and \$183,000, respectively, on these convertible notes as an increase to additional paid-in capital and interest expense.

NOTE 5 CONVERTIBLE PREFERRED STOCK

At September 30, 2013 (unaudited) and December 31, 2012, the authorized capital stock of the Company consisted of 165,148,953 shares of capital stock, comprising 100,000,000 shares of common stock and 65,148,953 shares of convertible preferred stock. All classes of the Company's stock a par value of \$0.001 per share.

At September 30, 2013 (unaudited) and December 31, 2012, convertible preferred stock consisted of approximately the following:

	Number of shares authorized	Number of shares issued and outstanding	Proceeds, net of issuance costs	Liquidation preference
Series A-1	17,874,137	17,874,137	\$ 39,954,000	\$ 23,851,000
Series B-1	12,871,729	12,841,729	10,347,000	11,237,000
Series C-1	12,481,837	12,481,834	8,354,000	8,762,000
Series D-1	21,921,253	21,921,253	12,012,000	16,660,000
	65,148,956	65,118,953	\$ 70,667,000	\$ 60,510,000

The significant features of the Company's convertible preferred stock are as follows:

Dividends The holders of Series D-1 are entitled to receive noncumulative dividends, prior and in preference to the declaration or payment of any dividend or distribution to the holders of Series C-1, Series B-1, Series A-1, and common stock, at the per annum rate of 8% of the original issuance price as adjusted for stock splits, stock dividends, and stock combinations, when and if declared by the Board of Directors.

The holders of Series C-1 and Series B-1 are entitled to receive noncumulative dividends, prior and in preference to the declaration, or payment of any dividend or distribution to the holders of Series A-1 and common stock, at the per annum rate of 8% of the original issuance price as adjusted for stock splits, stock dividends, and stock combinations, when and if declared by the Board of Directors. The original issuance price per share for Series D-1, Series C-1, Series B-1, and Series A-1 is \$0.76, \$0.702, \$0.87505, and \$1.33439, respectively. As of December 31, 2012, no dividends have been declared.

Table of Contents

Liquidation In the event of any liquidation, dissolution, or winding up of the Company, either voluntary or involuntary, the holders of Series D-1 are entitled to receive, prior and in preference to any distribution of any of the assets or surplus funds of the Company to the holders of Series C-1, Series B-1, Series A-1, and common stock, an amount equal to the original issuance price for each outstanding shares of \$0.76 per share, plus all declared but unpaid dividends on such shares.

Thereafter, if and only if payment of the amount required to be paid to Series D-1 is made in full, the holders of Series C-1 and Series B-1 are entitled to receive, prior and in preference to any distribution of any of the assets or surplus funds of the Company to the holders of Series A-1 and common stock, an amount per share in cash equal to \$0.702 and \$0.87505, respectively, plus all declared but unpaid dividends on such shares.

Thereafter, if and only if payment of the amount required to be paid to Series D-1, Series C-1, and Series B-1 is made in full, the holders of Series A-1 are entitled to receive, prior and in preference to any distribution of any of the assets or surplus funds of the Company to the holders of common stock, an amount per share in cash equal to \$1.33439, plus all declared but unpaid dividends on such shares.

After payment has been made to the holders of convertible preferred stock for the full amounts to which they are entitled, then all of the remaining assets of the Company available for distribution are distributed ratably among the holders of common stock.

Conversion Each share of convertible preferred stock is convertible at the option of the holder into shares of common stock of the Company as determined by dividing the original issuance price by the then effective conversion price for such series. The initial conversion price per share of Series D-1, Series C-1, Series B-1, and Series A-1 is \$0.76, \$0.702, \$0.83273, and \$1.17973, respectively.

Each share of convertible preferred stock automatically converts into the number of shares of common stock into which such shares are convertible at the then effective conversion rate upon the closing of an initial public offering resulting in aggregate cash proceeds of not less than \$35,000,000 and a per share offering price of common stock of at least \$1.50.

Voting rights The holder of each share of convertible preferred stock has voting rights equal to the number of shares of common stock into which it is convertible and votes together as one class with the common stock. Each share of common stock is entitled to one vote.

NOTE 6 WARRANTS

The following table summarizes the warrants issued and outstanding as of September 30, 2013 (unaudited):

Description of warrants	Issuance date	Warrants issued	Warrants outstanding	Fair value of		Expiration date
				price	at issuance	
Common stock	December 2004	18,000	18,000	\$ 2.50	\$ 54,000	December 2014
Convertible preferred stock	September 2008	31,524	31,524	\$ 0.88	\$ 26,000	June 2018
Common stock	March 2009	5,577,081	5,577,081	\$ 0.20	\$ 436,000	March 2014

Edgar Filing: AtriCure, Inc. - Form 424B5

Common stock	March - August 2010	365,000	365,000	\$ 0.20	\$ 36,000	March - August 2017
Common stock	December 2011	50,000	50,000	\$ 0.20	\$ 3,000	December 2021
Convertible preferred stock	December 2011	458,224	458,224	\$ 0.76	\$ 187,000	December 2021
Convertible preferred stock	March 2013	394,737	394,727	\$ 0.76	\$ 94,000	December 2023

F-18

Table of Contents

In December 2011, the Company issued a warrant to purchase 50,000 shares of common stock at \$0.20 per share. The warrant was issued in conjunction with a December 2011 term loan and amendment to the growth capital line entered in November 2009 (Note 4). This warrant is currently exercisable and expires in December 2021. The Company valued the warrant using the Black-Scholes option pricing model, which management has determined approximates fair value, with the following weighted-average assumptions: fair market value of \$0.12 per share, volatility of 45%, term of ten years, and a risk-free interest rate of 1.89%. The fair value of this warrant of approximately \$3,000 was recorded as additional paid-in capital and as prepaid interest expense and is being amortized to interest expense over the remaining life of the loan agreement.

In December 2011, the Company issued a warrant to purchase 458,224 shares of Series D-1 at \$0.76 per share. The warrant was issued in conjunction with a December 2011 amendment to the growth capital line that included the issuance of term loans. This warrant is currently exercisable and expires in December 2021. The Company valued the warrant using the Black-Scholes option pricing model, which management has determined approximates fair value, with the following weighted-average assumptions: fair market value of \$0.76 per share, volatility of 45%, term of ten years, and a risk-free interest rate of 1.89%. The fair value of this warrant of approximately \$187,000 was recorded as additional paid-in capital and prepaid interest expense and is being amortized to interest expense over the remaining life of the loan agreement.

In March 2013 the Company issued a warrant to purchase 394,737 shares of Series D-1 for \$0.76 per share. The warrant was issued in conjunction with a \$10,000,000 secured promissory note. This warrant is currently exercisable and expires in December 2023. The Company valued the warrant using the Black-Scholes option pricing model, which management has determined approximates fair value, with the following weighted-average assumptions: fair market value of \$0.76 per share, volatility of 38%, term of four years, and a risk-free interest rate of 1.89%. The fair value of this warrant of approximately \$94,000 was recorded as a liability and prepaid interest expense and is being amortized to interest expense over the remaining life of the loan agreement. The warrants have been remeasured at September 30, 2013 (unaudited), with approximately no change in fair value.

NOTE 7 NOTES RECEIVABLE FROM STOCKHOLDERS

During 2003, the Company received full recourse promissory notes totaling approximately \$1,465,000 from certain employees to exercise their stock options. The notes bear interest at a rate of 1.6% compounded semi-annually and are collateralized by the restricted common stock issued under the exercise of the options. The notes are due and payable in full on October 15, 2011 with interest payable in arrears. As of December 31, 2012, the due date was not extended and the stockholders are in default. During 2011, \$575,000 of these notes and accumulated interest thereon of \$77,000 was forgiven and 162,500 shares of common stock were cancelled in exchange for such forgiveness. As of December 31, 2012 and September 30, 2013 (unaudited), approximately \$113,000 of the notes remains outstanding and interest payable of approximately \$16,000 is in arrears.

During 2003, the Company received full recourse promissory notes totaling approximately \$969,000 from certain employees to exercise their warrants. The notes bear interest at a rate of 1.6% compounded semi-annually and are collateralized by the restricted common stock issued under the exercise of the options. The notes are due and payable in full on October 15, 2011 with interest payable in arrears. During 2011, \$1,064,000 of these notes and interest were forgiven. As of December 31, 2011, there is no outstanding balance payable.

During 2011, the Company cancelled notes receivable and accrued interest of \$1,716,000 upon the return of 308,299 shares of common stock.

During 2009, the Company received recourse promissory notes totaling approximately \$792,000 from certain employees to exercise their stock options. The notes bear interest at a rate of 0.8% and are collateralized by the restricted common stock issued under the exercise of the options. The notes are due and payable in full on May 14, 2015 with interest payable in arrears. As of December 31, 2012, \$792,000 of the notes remain outstanding and interest payable of approximately \$22,000 is in arrears. In 2013 these notes were paid in full.

F-19

Table of Contents**NOTE 8 STOCK OPTION PLAN**

Stock-based compensation expense for all share-based payment awards granted after January 1, 2006, and for previous awards modified, repurchased, or cancelled after January 1, 2006, is based on the grant-date calculated value. The Company recognizes these compensation costs, net of an estimated forfeiture rate, and recognizes the compensation costs for only those shares expected to vest on a straight-line basis over the requisite service period of the award, which is generally the option vesting term of four years. The Company estimated the forfeiture rate for the nine months ended September 30, 2013 (unaudited) and the years ended December 31, 2012 and 2011 based on its historical experience for annual grant years where the majority of the vesting terms have been satisfied.

For the nine months ended September 30, 2013 and 2012 (unaudited) and the years ended December 31, 2012 and 2011, the Company recorded stock-based compensation expense of approximately \$291,000, \$185,000, \$246,000, and \$293,000, respectively.

In September 2008, the Company adopted the 2008 Equity Incentive Plan (the Plan). The Plan served as the successor to the Company's 1998 Stock Option Plan. Pursuant to the terms of the Plan, 13,901,908 shares of common stock have been reserved for future issuance.

Options granted under the Plan vest over a period not to exceed five years and are exercisable for periods not exceeding ten years. Incentive and non-qualified stock options granted to stockholders who own greater than 10% of the Company's outstanding stock at the date of grant must be issued at not less than 110% of the estimated fair value of the common stock on the date of grant. Incentive and non-qualified stock options granted to any other employee, director or consultant must be issued at a price no less than 100% or 85%, respectively, of the estimated fair value of the common stock on the date of grant. Generally, options granted under the Plan are immediately exercisable and vest ratably over four years. Unvested stock option exercises are subject to repurchase upon termination of the holder's status as an employee or consultant. At December 31, 2012, there were zero shares that had been early exercised that were subject to the Company's repurchase right at that date.

In February 2013, the Company offered eligible participants the decision to exchange certain outstanding options to purchase shares of the Company's common stock granted under the Plan for new options the Company granted under the Plan. The new options have an exercise price of \$0.05 per share. In March 2013, 8,697,352 shares were exchanged.

Stock option activity for the nine months ended September 30, 2013 is as follows (unaudited):

	Shares	Weighted average exercise price per share	Weighted average remaining contractual life (in years)
Outstanding at December 31, 2012	9,681,865	\$ 0.22	7.29
Options granted	9,806,230	\$ 0.05	
Options exercised	(25,000)	\$ 0.05	
Options cancelled/forfeited/expired	(9,523,365)	\$ 0.20	
Outstanding at September 30, 2013	9,939,730	\$ 0.07	6.97

Vested and expected to vest at				
September 30, 2012 (1)	9,568,667	\$	0.07	6.90
Exercisable at September 30, 2013	7,438,239	\$	0.07	6.97

- (1) The expected to vest options are the result of applying the pre-vesting forfeiture rate assumptions to total outstanding options.

F-20

Table of Contents

Stock option activity for the year ended December 31, 2012 is as follows:

	Shares	Weighted average exercise price per share	Weighted average remaining contractual life (in years)
Outstanding at December 31, 2011	9,280,524	\$ 0.23	7.88
Options granted	1,616,780	\$ 0.20	
Options exercised	(30,750)	\$ 0.20	
Options cancelled/forfeited/expired	(1,184,689)	\$ 0.36	
Outstanding at December 31, 2012	9,681,865	\$ 0.22	7.29
Vested and expected to vest at December 31, 2012 (1)	9,341,250	\$ 0.22	7.28
Exercisable at December 31, 2012	6,857,748	\$ 0.22	6.83

(1) The expected to vest options are the result of applying the pre-vesting forfeiture rate assumptions to total outstanding options.

The total pretax intrinsic value of options exercised during nine months ended September 30, 2013 and 2012 (unaudited) and the years ended December 31, 2012 and 2011 was zero. The intrinsic value is the difference between the estimated fair value of the Company's common stock at the date of exercise and the exercise price for in-the-money options. The weighted average grant date calculated fair value of options granted during the years ended December 31, 2012 and 2011 was \$0.028 and \$0.038, respectively. The weighted average grant date calculated fair value of options granted during the nine month period ended September 30, 2013 and 2012 (unaudited) was \$0.015 and \$0.028, respectively.

As of September 30, 2013 (unaudited) and December 31, 2012, there was approximately \$119,000 and \$95,000, respectively, of unamortized stock-based compensation cost related to unvested stock options which is expected to be recognized over a weighted average period of 1.7 years.

Cash received from option exercises and purchases of shares under the Plan for the nine months ended September 30, 2013 and 2012 (unaudited) and the year ended December 31, 2012 was approximately \$1,300, \$6,200 and \$6,200, respectively.

The calculated fair value of option grants was estimated using the Black-Scholes option pricing model with the following weighted average assumptions:

	Nine months ended September 30,	
	2013 (unaudited)	2012 (unaudited)
Expected dividend yield (1)	0%	0%

Edgar Filing: AtriCure, Inc. - Form 424B5

Risk-free interest rate (2)	0.40% - 2.48%	0.63% - 1.42%
Expected volatility (3)	38%	45%
Expected life (in years) (4)	6.97	5.93

	Stock options	
	Years ended December 31,	
	2012	2011
Expected dividend yield (1)	0%	0%
Risk-free interest rate (2)	0.63% - 1.42%	1.16% - 2.64%
Expected volatility (3)	45%	45%
Expected life (in years) (4)	5.93	5.91

F-21

Table of Contents

- (1) The Company has no history or expectation of paying cash dividends on its common stock.
- (2) The risk-free interest rate is based on the U.S. Treasury yield for a term consistent with the expected life of the awards in effect at the time of grant.
- (3) The Company estimates the volatility of its common stock at the date of grant based on the implied volatility of publicly traded options on its common stock, with a term of one year or greater. For the nine months ended September 30, 2013 (unaudited) and the years ended December 31, 2012 and 2011, the Company used an equally weighted average of trailing volatility and market based implied volatility for the computation.
- (4) The expected life represents the period of time that options granted are expected to be outstanding.

NOTE 9 INCOME TAXES

Income taxes have been provided in accordance with ASC 740, *Accounting for Income Taxes*. ASC 740 requires that the tax benefit of net operating losses, temporary differences and credit carryforwards be recorded as an asset to the extent that management assesses that realization is more likely than not. Realization of the future tax benefits is dependent on the Company's ability to generate sufficient taxable income within the carryforward period. Because of the Company's recent history of operating losses, management believes that recognition of the deferred tax assets arising from the above-mentioned future tax benefits is currently not likely to be realized and, accordingly, has provided a valuation allowance.

As of December 31, 2012 and 2011, the Company had deferred tax assets of approximately \$23,629,000 and \$21,077,000, respectively. Deferred tax assets primarily relate to net operating loss and tax credit carryforwards. Realization of the deferred tax assets is dependent upon future taxable income, if any, the amount and timing of which are uncertain. Accordingly, the net deferred tax assets have been fully offset by a valuation allowance. The valuation allowance increased by approximately \$2,552,000 during 2012 and approximately \$1,585,000 during 2011.

As of December 31, 2012 and 2011, the Company had federal NOL carryforwards of approximately \$64,351,000 and \$56,843,000, respectively. The Company also had federal research and development tax credit carryforwards of approximately \$773,000 and \$688,000, respectively. The federal NOL and tax credit carryforwards will expire at various dates beginning in 2023 if not utilized.

As of December 31, 2012 and 2011, the Company had state NOL carryforwards of approximately \$39,509,000 and \$32,137,000, respectively. The Company also had state research and development tax credit carryforwards of approximately \$918,000 and \$798,000, respectively. The state net operating loss carryforwards will expire at various dates beginning in 2017 if not utilized. The state tax credit carryforwards do not expire.

Utilization of the net operating loss carryforwards and credits may be subject to a substantial annual limitation due to the ownership change limitations provided by the Internal Revenue Code No. 382, as amended and similar state provisions. In 2011, the Company completed a study and determined there had been changes in ownership that would restrict the Company's ability to utilize approximately \$18,627,000 of federal NOL carryforwards since inception. The deferred tax assets at December 31, 2012 and 2011 have been adjusted for the restriction.

A number of the Company's tax returns remain subject to examination by taxing authorities. These include U.S. federal returns for 1999 and later years, and tax returns for certain states for 2003 and later years.

NOTE 10 BENEFIT PLANS

401(k) plan The Company has a 401(k) plan in which each participant may elect to contribute portions of their salary, subject to statutory limitations, and provides for a matching contribution, as defined by the plan.

Table of Contents**NOTE 11 RELATED PARTY TRANSACTIONS**

On August 10, 2005, the Company completed a series of agreements with BSC, which included the following:

A securities purchase agreement, whereby BSC purchased 666,667 shares of the Company's Series D convertible preferred stock (Series D) for cash at \$15.00 per share, for aggregate cash proceeds of approximately \$10,000,000;

Amendment to the existing merger agreement and securities purchase agreement, whereby, among other items, BSC's exclusive option to acquire the Company was extended, the contingent payments payable by BSC under the merger agreement were increased, and certain financial and operating covenants were relaxed; and

Asset purchase, distribution, supply, and technology license agreements resulting in the transfer to the Company the right to design, develop, manufacture, and sell BSC's COBRA product.

In connection with these agreements, the Company recorded the issuance of Series D based on the sum of: i) cash proceeds of approximately \$10,000,000 received from BSC and ii) the fair value of BSC's COBRA product line transferred to the Company, based on an independent valuation of approximately \$15,420,000 for an aggregate value of approximately \$25,420,000 or \$38.13 per share. The value of the COBRA product line has been recorded as an intangible asset, and is being amortized over the term of the technology license of 20 years.

On September 17, 2007, the Company entered into several agreements with BSC. These agreements terminated BSC's option to acquire the Company, reduced the royalty payable on sale of COBRA technology products from 12% to 3%.

NOTE 12 COMMITMENTS AND CONTINGENCIES

Operating leases The Company leases its facilities under noncancelable operating leases expiring in December 2014. Rent expense related to the Company's operating leases was approximately \$417,000 and \$409,000 for the years ended December 31, 2012 and 2011, respectively. Rent expense related to the Company's operating leases was approximately \$344,000 and \$312,000 for the nine month period ended September 30, 2013 and 2012 (unaudited), respectively.

Future minimum payments under noncancelable leases are approximately as follows:

Years ending December 31:	
2013	\$ 446,000
2014	464,000
	\$ 910,000

As of September 30, 2013 (unaudited), the future minimum payments under noncancelable leases are approximately \$111,000 for the three months remaining in the year ending December 31, 2013, and \$464,000 for the year ended December 31, 2013.

General litigation From time to time, the Company becomes involved in legal proceedings arising from the ordinary course of business. The Company records a provision for a liability when management believes that it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Management is not aware of any matters that will have a material adverse affect on the financial position, results of operations, or cash flows of the Company at September 30, 2013.

NOTE 13 SALE OF PRODUCT LINE

On July 1, 2011, the Company sold its Cannula Product line to Sorin Group USA, Inc. (Sorin Group USA) for a gross purchase consideration of \$5,000,000, less legal, banking, and other fee expenses of \$1,131,000. The Company transferred approximately \$418,000 of inventory and \$49,000 of equipment to Sorin Group USA and recorded a gain of approximately \$3,401,000.

Table of Contents

NOTE 14 SUBSEQUENT EVENTS (UNAUDITED)

On October 10, 2013 the Company sold substantially all of its assets related to its CABG product line for \$17,075,000 in cash, plus \$1,000,000 of transition services to be provided to the acquirer after completion of the sale, of which \$500,000 has been collected to date. Assets sold to the acquirer included intellectual property, inventory and equipment. The Company used part of the proceeds from the sale of its CABG assets to pay off the \$10,000,000 secured promissory note entered on March 21, 2013.

On December 31, 2013 the Company was acquired in a merger for \$34,000,000 in common stock of the acquirer, plus the Company's cash at close after the payment of transaction costs, severance, payments to unaccredited shareholders, and bonus payments. In addition, \$3,400,000 of stock and cash was set aside in escrow to be released to the Company's shareholders after fifteen months if there are no claims of the acquirer related to representations and warranties made by the Company under the merger agreement. Further, if certain sales milestones are achieved in 2014 and 2015, up to another \$26,000,000 in cash or stock of the acquirer may be distributed to the Company's shareholders.

Table of Contents

UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION

The following unaudited pro forma condensed combined financial information is presented to give effect to the acquisition of Endoscopic Technologies, Inc. (Estech) by AtriCure, Inc. and subsidiaries (AtriCure or the Company), the Acquisition , as announced on December 19, 2013 and subsequently closed on December 31, 2013.

The unaudited pro forma condensed consolidated financial information was prepared using (i) the audited consolidated financial statements of AtriCure for the year ended December 31, 2012 and the unaudited condensed consolidated financial statements of AtriCure for the nine months ended September 30, 2013 incorporated by reference in this prospectus, (ii) the audited consolidated financial statements of Estech for the fiscal year ended December 31, 2012 and the unaudited consolidated financial statements of Estech for the nine months ended September 30, 2013 included elsewhere in this prospectus (iii) the removal of amounts related to certain operations disposed of by Estech prior to the Acquisition, (iv) the preliminary purchase price allocation of the Estech acquisition, a summary of which is included in Note 2 to this unaudited pro forma condensed consolidated financial information, and (v) the assumptions and adjustments described in the notes accompanying this unaudited pro forma condensed consolidated financial information. The pro forma condensed combined statement of continuing operations reflects the Acquisition as if it had been completed on January 1, 2012, and the pro forma condensed combined balance sheet reflects the Acquisition as if it had been completed on September 30, 2013.

The Estech acquisition was accounted for using the acquisition method of accounting. Under the acquisition method of accounting, the purchase price is required to be allocated to the underlying tangible and intangible assets acquired and liabilities assumed based on their respective fair market values. Any purchase price in excess of the fair market value of the acquired tangible and intangible assets is required to be allocated to goodwill in our condensed combined balance sheet as of the end of the period in which the acquisition closed. We performed appraisals necessary to derive preliminary fair values of the tangible and intangible assets acquired and liabilities assumed, the amounts of assets and liabilities arising from contingencies, and the amount of goodwill to be recognized as of the acquisition date, and the related preliminary allocation of the purchase price.

This unaudited pro forma condensed combined financial information should be read in conjunction with the historical consolidated audited and unaudited financial statements of AtriCure and Estech and the related audited and unaudited notes thereto included in or incorporated by reference in this prospectus.

Table of Contents**AtriCure, Inc. and Subsidiaries and Endoscopic Technologies, Inc.****Condensed Combined Balance Sheet and Pro Forma Adjustments****As of September 30, 2013****(Unaudited)**

(amounts in thousands)

	Historical	Historical		Pro	Pro
	AtriCure,	Endoscopic	Elimination	Forma	Forma
	Inc.	Technologies,	of CABG	Adjustments	Combined
Assets					
Current assets:					
Cash and cash equivalents	\$ 25,821	\$ 3,093	\$ 7,075 a)	\$ (10,168) b)	\$ 25,821
Short-term investments	3,864				3,864
Accounts receivable, less allowance for doubtful accounts	11,031	2,825	(914) c)		12,942
Inventories	7,062	3,162	(651) d)	(142) e)	9,431
Other current assets	779	648			1,427
Total current assets	48,557	9,728	5,510	(10,310)	53,485
Property and equipment, net	4,135	1,452	(105) f)	128 g)	5,610
Long-term investments	4,678				4,678
Goodwill				28,470 h)	28,470
Intangible assets	23	10,868	(1,146) i)	341 j)	10,086
Other assets	244	51	(51) k)		244
Total assets	\$ 57,637	\$ 22,099	\$ 4,208	\$ 18,629	\$ 102,573
Liabilities and Stockholders					
Equity					
Current liabilities					
Accounts payable	\$ 5,720	\$ 1,609	\$ (256) l)	\$	\$ 7,073
Accrued liabilities	8,518	1,664		7,919 m)	18,101
Current maturities of debt and capital leases	2,037	1,818	(1,818) n)		2,037
Total current liabilities	16,275	5,091	(2,074)	7,919	27,211
Long-term debt and capital lease obligations	4,922	8,182	(8,182) n)		4,922
Other liabilities	195	94	(94) o)		195
Total liabilities	21,392	13,367	(10,350)	7,919	32,328

Stockholders' Equity:

Convertible preferred stock		70,667		(70,667) p)	
Common stock	21	4		(4) p)	21
Additional paid-in capital	153,420	17,338		16,662 p)	187,420
Accumulated other comprehensive income (loss)	37				37
Accumulated deficit	(117,233)	(79,125)	14,558 q)	64,567 p)	(117,233)
Notes receivables from Stockholders		(152)		152 p)	
Total stockholders' equity	36,245	8,732	14,558	10,710	70,245
Total liabilities and stockholders' equity	\$ 57,637	\$ 22,099	\$ 4,208	\$ 18,629	\$ 102,573

F-26

Table of Contents**AtriCure, Inc. and Subsidiaries and Endoscopic Technologies, Inc.****Condensed Combined Statement of Continuing Operations and Pro Forma Adjustments****For the Nine Months ended September 30, 2013****(Unaudited)**

(amounts in thousands, except for share data)

	Historical			Pro	Pro Forma
	AtriCure, Inc.	Endoscopic Technologies, Inc.	Elimination of CABG	Forma Adjustments	Pro Forma Combined
Revenue	\$ 60,005	\$ 14,913	\$ (6,348) r)		\$ 68,570
Cost of revenue	16,111	4,038	(1,164) s)	592 t)	19,577
Gross profit	43,894	10,875	(5,184)	(592)	48,993
Operating expenses:					
Research and development expenses	9,792	2,395		(159) u)	12,028
Selling, general and administrative expenses	40,155	11,290		(429) v)	51,016
Total operating expenses	49,947	13,685		(588)	63,044
Loss from operations	(6,053)	(2,810)	(5,184)	(4)	(14,051)
Other income (expense):					
Interest expense	(428)	(1,592)	939 w)	73 x)	(1,008)
Interest income	8	94			102
Other	5	(12)	12 y)		5
Loss before income tax expense	(6,468)	(4,320)	(4,233)	69	(14,952)
Income tax expense	14				14
Net income (loss)	\$ (6,482)	\$ (4,320)	\$ (4,233)	69	\$ (14,966)
Basic and diluted net loss per share	\$ (0.32)				\$ (0.67)
Weighted average shares outstanding-basic and diluted	20,311			2,126 z)	22,437

Table of Contents**AtriCure, Inc. and Subsidiaries and Endoscopic Technologies, Inc.****Condensed Combined Statement of Continuing Operations and Pro Forma Adjustments****For the Year ended December 31, 2012****(Unaudited)**

(amounts in thousands, except for share data)

	Historical	Endoscopic		Pro	Pro
	AtriCure,	Technologies,	Elimination	Forma	Forma
	Inc.	Inc.	of CABG	Adjustments	Combined
Revenue	\$ 70,247	\$ 19,629	\$ (7,922) aa)		\$ 81,954
Cost of Revenue	20,233	5,509	(1,445) bb)	677 cc)	24,974
Gross profit	50,014	14,120	(6,477)	(677)	56,980
Operating expenses:					
Research and development expenses	12,147	3,137		(246) dd)	15,038
Selling, general and administrative expenses	45,065	16,016		(405) ee)	60,676
Total operating expenses	57,212	19,153		(651)	75,714
Loss from operations	(7,198)	(5,033)	(6,477)	(26)	(18,734)
Other income (expense):					
Interest expense	(802)	(1,002)	816 ff)		(988)
Interest Income	11	225			236
Other	505	(2,992)	2,992 gg)		505
Loss before income tax expense	(7,484)	(8,802)	(2,669)	(26)	(18,981)
Income tax expense	50				50
Net loss	\$ (7,534)	\$ (8,802)	\$ (2,669)	\$ (26)	\$ (19,031)
Basic and diluted net loss per share	\$ (0.47)				\$ (1.04)
Weighted average shares outstanding-basic and diluted	16,190			2,126 hh)	18,316

Table of Contents**AtriCure, Inc. and Endoscopic Technologies, Inc..****Notes to Unaudited Pro Forma Condensed Combined Financial Information****Note 1. Basis of Presentation**

The historical financial information has been adjusted to give pro forma effect to events that are (i) directly attributable to the Acquisition and related transactions, (ii) factually supportable, and (iii) with respect to the unaudited pro forma condensed combined statements of continuing operations, expected to have a continuing impact on the combined results. The pro forma adjustments are preliminary and based on estimates of the fair value and useful lives of the assets acquired and liabilities assumed and have been prepared to illustrate the estimated effect of the Acquisition and certain other adjustments. The final determination of the purchase price allocation will be based on the fair values of assets acquired and liabilities assumed as of the date the Acquisition closes, and could result in significant changes to the unaudited pro forma condensed combined financial information, including goodwill.

This unaudited pro forma condensed consolidated financial information should be read in conjunction with the historical consolidated audited and unaudited financial statements of AtriCure, Inc. and Estech and the related audited and unaudited notes thereto included elsewhere in this prospectus.

Note 2. Estech Acquisition

On December 31, 2013, AtriCure completed its acquisition of Estech, pursuant to the Merger Agreement, dated as of December 19, 2013, with Niners Merger Sub, LLC, a Delaware limited liability company and wholly-owned subsidiary of AtriCure (Merger Sub), Estech and Fortis Advisors LLC, a Delaware limited liability company. Under the terms of the Merger Agreement, Estech merged with and into Merger Sub and Merger Sub survived as a wholly owned subsidiary of AtriCure (the Merger).

The aggregate consideration paid to Estech's former stockholders in the Merger was \$34 million paid through the issuance of 2,126,343 shares of AtriCure common stock valued at \$15.99 under the terms of the Merger Agreement and up to \$26 million to be paid in additional consideration based on the achievement of certain performance based milestones. The purchase price is subject to adjustments based on Estech's working capital and certain expenses incurred by Estech in connection with the consummation of the transactions contemplated by the Merger Agreement (the Closing Merger Consideration). All outstanding Estech equity awards were cancelled as of closing date of Merger, the preliminary estimated purchase price of the acquisition is as follows:

Fair Value of shares issued	\$ 34,000
Preliminary Fair Value of Contingent Consideration	7,508
Total Purchase Price	\$ 41,508

Preliminary Purchase Price Allocation

Pursuant to the Company's business combinations accounting policy, the total preliminary purchase price for Estech was allocated to the preliminary net tangible and intangible assets based upon their preliminary fair values as set forth below. The excess of the preliminary purchase price over the preliminary net tangible assets and preliminary intangible assets was recorded as goodwill.

Table of Contents

The Company's preliminary purchase price allocation for Estech is as follows:

Fair Value of Acquired Working Capital	\$ 1,500
Recognize long-term assets at fair value	
Property and Equipment	1,475
Identified Intangible Assets	
Fusion Technology (15 year life)	9,100
Clamp and Probe Technology (10 year life)	755
Trade Name (1 year life)	208
Goodwill	28,470
Total Purchase Price	\$ 41,508

The preliminary purchase price allocation is based on preliminary estimates and assumptions, and is subject to change during the purchase price measurement period as the Company finalizes its estimates of the fair value of assets acquired and liabilities assumed as of the Acquisition date.

Note 3. Notes to Unaudited Pro Forma Condensed Combined Balance Sheet as of September 30, 2013

The unaudited pro forma condensed combined balance sheet presented above reflects the following specific adjustments:

a) Cash	<i>Elimination of CABG</i>	
To reflect the cash proceeds from the sale of a product line sold by Estech before the acquisition of Estech by AtriCure		\$ 17,075
To reflect cash used to settle secured promissory note before the acquisition of Estech by AtriCure		(10,000)
Total adjustments to cash		\$ 7,075
b) Cash	<i>Proforma Adjustments</i>	
To reflect Estech cash not transferred as detailed in the merger agreement		\$ (10,168)
c) Accounts receivable, less allowance for doubtful accounts	<i>Elimination of CABG</i>	
To reflect net accounts receivable related to a product line sold by Estech before the acquisition of Estech by AtriCure		\$ (914)
d) Inventory	<i>Elimination of CABG</i>	
To reflect inventory of a product line sold by Estech before the acquisition of Estech by AtriCure		\$ (651)
e) Inventory	<i>Pro Forma Adjustments</i>	\$ (142)

To reflect a policy difference to reduce Estech product inventory issued to sales representatives as AtriCure expenses this type of inventory when issued

(Note: No adjustment to fair value of inventory is reflected as inventory as stated approximates fair value due to its estimated cost to sell and normal profit margin.)

f) Property and equipment, net *Elimination of CABG*

To reflect net book value of equipment of a product line sold by Estech before the acquisition of Estech by AtriCure	\$ (105)
--	----------

g) Property and equipment, net *Pro Forma Adjustments*

To reverse net book value of existing property and equipment	\$ (1,347)
--	------------

To record fair value of acquired property and equipment	1,475
---	-------

Total adjustments to property and equipment, net	\$ 128
--	--------

Table of Contents

h) Goodwill <i>Pro Forma Adjustments</i>	
To adjust for purchase consideration in excess of fair value of net assets acquired as of December 31, 2013 valuation date	\$ 28,470
i) Intangible assets <i>Elimination of CABG</i>	
To reflect net book value of intangible assets such as patents and licenses related to a product line sold by Estech before the acquisition of Estech by AtriCure	\$ (1,146)
j) Intangible assets <i>Pro Forma Adjustments</i>	
To reverse net book value of existing Estech intangible assets	\$ (9,722)
To record fair value of acquired intangible assets such as acquired technology and trade name	10,063
Total adjustments to intangible assets	\$ 341
k) Other assets <i>Elimination of CABG</i>	
To reflect deferred financing fees written off related to secured promissory note paid off before the acquisition of Estech by AtriCure	\$ (51)
l) Accounts payable <i>Elimination of CABG</i>	
To reflect accounts payable related to a product line sold by Estech before the acquisition of Estech by AtriCure	\$ (256)
m) Accrued liabilities <i>Pro Forma Adjustments</i>	
To reflect fair value of contingent consideration related to the earn-out provisions in the merger agreement between Estech and AtriCure	\$ 7,508
To reflect assumed obligations to seller based on excess closing working capital over \$1,500 as detailed in the merger agreement	411
Total adjustments to accrued liabilities	\$ 7,919
n) Debt and capital leases <i>Elimination of CABG</i>	
Current maturities of debt and capital leases	
To reflect settlement of secured promissory note by Estech before the acquisition of Estech by AtriCure-current portion	\$ (1,818)
Long-term debt and capital lease obligations	
To reflect settlement of secured promissory note by Estech before the acquisition of Estech by AtriCure long-term portion	\$ (8,182)
o) Other Liabilities <i>Elimination of CABG</i>	
	\$ (94)

To reflect settlement of Estech warrant liability associated with settled secured promissory note prior to closing of acquisition of Estech by AtriCure

p) Stockholders Equity *Proforma Adjustments*

Convertible preferred stock

To reverse Series D-1 convertible preferred stock of Estech	\$ (12,012)
To reverse Series C-1 convertible preferred stock of Estech	(8,354)
To reverse Series B-1 convertible preferred stock of Estech	(10,347)
To reverse Series A-1 convertible preferred stock of Estech	(39,954)

Total adjustments to Convertible preferred stock	\$ (70,667)
--	-------------

Common stock

To reverse common stock of Estech	\$ (4)
To record \$.001 per share par value of 2.1 million common shares of AtriCure issued to Estech shareholders as merger consideration	0

Total adjustments to Common stock	\$ (4)
-----------------------------------	--------

Table of Contents

Additional paid-in capital	
To reverse additional paid-in capital of Estech	\$ (17,338)
To record additional paid-in capital related to issuance of common shares of AtriCure issued to Estech shareholders as merger consideration (2.1 million shares of AtriCure stock x \$15.99 price per share per the merger agreement)	34,000
Total adjustments to property and equipment, net	\$ 16,662
Accumulated deficit	
To reverse accumulated deficit of Estech	\$ (64,567)
Notes receivables from stockholders	
To reverse notes receivables from stockholders of Estech	\$ 152
q) Accumulated deficit <i>Elimination of CABG</i>	
To reflect gain on sale of product line sold by Estech before the acquisition of Estech by AtriCure	\$ 14,558

Note 4. Notes to Unaudited Pro Forma Condensed Combined Statement of Continuing Operations for the nine months ended September 30, 2013

The unaudited pro forma condensed statement of continuing operations presented above reflects the following specific adjustments:

r) Revenue <i>Elimination of CABG</i>	
To reflect elimination of revenue related to a product line sold by Estech before the acquisition of Estech by AtriCure	\$ (6,348)
s) Cost of revenue <i>Elimination of CABG</i>	
To reflect elimination of cost of revenue related to a product line sold by Estech before the acquisition of Estech by AtriCure	\$ (1,164)
t) Cost of revenue <i>Pro Forma Adjustments</i>	
Reclassification of certain excise taxes to cost of revenue from interest expense to conform with AtriCure presentation	\$ 73
Reclassification of personnel expenses to cost of revenue from selling, general and administrative expenses to conform with AtriCure presentation	293
Reclassification of personnel expenses to cost of revenue from research and development expense to conform with AtriCure presentation	165
Reclassification of laboratory and warehousing facilities cost allocation to cost of revenue from selling, general and administrative expenses to conform with AtriCure presentation	61

Total adjustments to Cost of revenue	\$ 592
u) Research and development expenses <i>Pro Forma Adjustments</i>	
Reclassification of legal expenses related to patents from research and development expenses to selling, general and administrative expenses to conform with AtriCure presentation	\$ (104)
Reclassification of personnel expenses to cost of revenue from research and development expenses to conform with AtriCure presentation	(165)
Reclassification of laboratory and warehousing facilities cost allocation to research and development from selling, general and administrative expenses to conform with AtriCure presentation	110
Total adjustments to Research and development expenses	\$ (159)

F-32

Table of Contents

v) Selling, general and administrative expenses	<i>Pro Forma Adjustments</i>	
To reflect a policy difference to reduce Estech product inventory issued to sales representatives as AtriCure expenses this type of inventory when issued		\$ 142
Reclassification of legal expenses related to patents from research and development expenses to selling, general and administrative expenses to conform with AtriCure presentation		104
Reclassification of personnel expenses to cost of revenue from selling, general and administrative expenses to conform with AtriCure presentation		(293)
Reclassification of laboratory and warehousing facilities cost allocation to cost of revenue from selling, general and administrative expenses to conform with AtriCure presentation		(61)
Reclassification of laboratory and warehousing facilities cost allocation to research and development from selling, general and administrative expenses to conform with AtriCure presentation		(110)
To reverse amortization expense for existing Estech intangible assets		(722)
To record amortization expense for newly identified Estech intangible assets		511
Total adjustments to Selling, general and administrative expenses		\$ (429)
w) Interest expense	<i>Elimination of CABG</i>	
To eliminate interest expense for secured promissory note settled by Estech before the acquisition of Estech by AtriCure		\$ 939
x) Interest expense	<i>Pro Forma Adjustments</i>	
Reclassification of certain excise taxes to cost of revenue from interest expense to conform with AtriCure presentation		\$ 73
y) Other	<i>Elimination of CABG</i>	
To eliminate beneficial conversion feature and cost of warrants related to secured promissory note settled by Estech before the acquisition of Estech by AtriCure		\$ 12
z) Weighted average shares outstanding-Basic and diluted	<i>Pro Forma Adjustments</i>	
AtriCure shares to be issued in replacement of Estech common shares		2,126

Note 5. Notes to Unaudited Pro Forma Condensed Combined Statement of Continuing Operations for the year ended December 31, 2012

The unaudited pro forma condensed statement of continuing operations above reflects the following specific adjustments:

aa) Revenue	<i>Elimination of CABG</i>	
To reflect elimination of revenue related to a product line sold by Estech before the acquisition of Estech by AtriCure		\$ (7,922)

bb) Cost of revenue *Elimination of CABG*

To reflect elimination of cost of revenue related to a product line sold by Estech before the acquisition of Estech by AtriCure \$ (1,445)

cc) Cost of revenue *Pro Forma Adjustments*

Reclassification of personnel expenses to cost of revenue from selling, general and administrative expenses to conform with AtriCure presentation \$ 399

Table of Contents

Reclassification of personnel expenses to cost of revenue from research and development expense to conform with AtriCure presentation	204
Reclassification of laboratory and warehousing facilities cost allocation to cost of revenue from selling, general and administrative expenses to conform with AtriCure presentation	74
Total adjustments to Cost of revenue	\$ 677
dd) Research and development expenses <i>Pro Forma Adjustments</i>	
Reclassification of legal expenses related to patents from research and development expenses to selling, general and administrative expenses to conform with AtriCure presentation	\$ (175)
Reclassification of personnel expenses to cost of revenue from research and development expenses to conform with AtriCure presentation	(204)
Reclassification of laboratory and warehousing facilities cost allocation to research and development from selling, general and administrative expenses to conform with AtriCure presentation	133
Total adjustments to Research and development expenses	\$ (246)
ee) Selling, general and administrative expenses <i>Pro Forma Adjustments</i>	
To reflect a policy difference to reduce Estech product inventory issued to sales representatives as AtriCure expenses this type of inventory when issued	\$ 101
Reclassification of legal expenses related to patents from research and development expenses to selling, general and administrative expenses to conform with AtriCure presentation	175
Reclassification of personnel expenses to cost of revenue from selling, general and administrative expenses to conform with AtriCure presentation	(399)
Reclassification of laboratory and warehousing facilities cost allocation to cost of revenue from selling, general and administrative expenses to conform with AtriCure presentation	(74)
Reclassification of laboratory and warehousing facilities cost allocation to research and development from selling, general and administrative expenses to conform with AtriCure presentation	(133)
To reverse amortization expense for existing Estech intangible assets	(964)
To record amortization expense for newly identified Estech intangible assets	889
Total adjustments to Selling, general and administrative expenses	\$ (405)
ff) Interest expense <i>Elimination of CABG</i>	
To eliminate interest expense related to secured promissory note settled by Estech before the acquisition of Estech by AtriCure	\$ 816
gg) Other	
To eliminate beneficial conversion feature and cost of warrants related to secured promissory note settled by Estech before the acquisition of Estech by AtriCure	\$ 2,992
hh) Weighted average shares outstanding-Basic and diluted <i>Pro Forma Adjustments</i>	
AtriCure shares to be issued in replacement of Estech common shares	2,126

Note 6. Pro Forma Net Loss per Common Share

The pro forma basic and diluted net loss per common share is based on the weighted average number of common shares of AtriCure's common stock outstanding during the period as adjusted to reflect the shares of common stock issued as consideration in the Estech acquisition. The diluted weighted average number of common shares does not include outstanding stock options as their inclusion would be anti-dilutive.

F-34

Table of Contents

Shares

AtriCure, Inc.

Common Stock

PROSPECTUS SUPPLEMENT

Piper Jaffray

Sole Book-Running Manager

Canaccord Genuity

**Leerink
Barrington Research**

Stifel

